UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED JUNE 30, 2024
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________
COMMISSION FILE NUMBER: 000-54437
SUNHYDROGEN, INC.
(Exact name of registrant as specified in its charter)
Nevada | | 26-4298300 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
BioVentures Center, 2500 Crosspark Road, Coralville, IA 52241 |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code (805) 966-6566
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
None | | None | | None |
Securities registered pursuant to section 12(g)
of the Act: common stock, par value $0.001 per share
Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant
(1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated Filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☐ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. ☐
If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of the common stock
held by non-affiliates of the registrant, based upon the last sale price of the common stock of the registrant as of the last business
day of its most recently completed second fiscal quarter was approximately $65.0 million.
The number of shares of registrant’s common stock outstanding,
as of September 30, 2024 was 5,205,759,708.
DOCUMENTS INCORPORATED BY REFERENCE
None
TABLE OF CONTENTS
PART I
Item 1. Business.
Unless otherwise stated
or the context requires otherwise, references in this annual report on Form 10-K to “SunHydrogen”, the “Company”,
“we”, “us”, or “our” refer to SunHydrogen, Inc.
Overview
At SunHydrogen, our goal is
to replace fossil fuels with clean, renewable hydrogen.
Hydrogen is the most abundant
chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct left behind is pure
water, unlike hydrocarbon fuels such as oil, coal and natural gas that emit carbon dioxide and other harmful pollutants into the atmosphere.
However, naturally occurring hydrogen molecules are rare – so rare that today about 95% of all molecular hydrogen is produced from
steam reforming of natural gas (Source: US Department of Energy, Hydrogen Fuel Basics). This process is both economically and environmentally
unsound.
SunHydrogen is developing
an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source
of water. Our innovative solar hydrogen technology uses abundant and low-cost materials, requires no external power other than sunlight,
and is designed with scalability in mind. Its core components include a substrate, photovoltaic layers, and catalysts that integrate to
split water molecules into green hydrogen and oxygen. Just like a solar panel is comprised of multiple cells that generate electricity,
our hydrogen panel encases multiple hydrogen generators immersed in water. Each hydrogen generator autonomously splits water into hydrogen
and oxygen. Our technology has the potential to be one of – if not the most – economical green hydrogen solutions: Unlike
traditional water electrolysis for hydrogen, our process requires no external power other than sunlight and uses efficient and low-cost
materials.
We believe renewable hydrogen has already proven
itself to be a key solution in helping the world meet climate targets, and we believe our technology potentially offers solutions to the
challenges that the hydrogen future presents, including cost of production and transportation. Many of today’s green hydrogen producers
transport their product over long distances, so although the hydrogen itself is green, the delivery and transport infrastructure come
with a high carbon footprint and a significant capital investment. The SunHydrogen solution is fully self-contained, offering on-site
solar hydrogen generation and local distribution to eliminate carbon footprint altogether and significantly reduce capital investments
for transport and delivery.
Additionally, because our
process directly uses the electrical charges created by sunlight to generate hydrogen, our technology does not rely on grid power or require
the costly power electronics that conventional electrolyzers do.
With a target cost of $2.50/kg.,
we believe our solution has the potential to clear a path for green hydrogen to compete with natural gas hydrogen and gain mass market
acceptance as a true replacement for fossil fuels.
Our
technology is primarily developed at our independent laboratory in Coralville, Iowa. These development efforts are further supported through
sponsored research agreements with the University of Iowa and the University of Michigan, as well as collaborations with specialized industrial
partners and consultants.
Led by Chief Scientific Officer Dr. Syed Mubeen
and Director of Technology Dr. Joun Lee, our Iowa team continues to focus on developing tandem photoelectrosynthetic heterostructures
(nanoparticle-based tandem semiconductor units) and evaluating their manufacturability at scales suitable for commercialization. Over
the past year, the team has dedicated efforts to improving the performance and scaling up of our nanoparticle-based hydrogen generators.
In parallel, we have been actively exploring a
new methodology that utilizes commercially available, mass-produced thin-film PV cells and modules. These are re-engineered with our proprietary
hydrogen module design to enhance fault tolerance and increase hydrogen production efficiency. While this approach is built on principles
similar to our nanoparticle technology, it leverages a mature manufacturing platform, enabling a potentially faster market entry.
SunHydrogen remains fully committed to our patented
nanoparticle-based approach to green hydrogen production. However, this new methodology, which aligns closely with our nanoparticle technology,
benefits from an established manufacturing base. Our core mission remains the replacement of fossil fuel-derived hydrogen with truly green
hydrogen. If there is an opportunity to achieve this goal more quickly and enter the market sooner, we believe it is in our shareholders'
best interest to capitalize on our existing foundation and expertise to do so.
Over the past year, our Iowa team achieved significant
milestones in advancing our green hydrogen production technology toward commercialization. These accomplishments span both our nanoparticle-based
tandem semiconductor units and our innovative approach using thin-film PV cells and modules, as further described below.
Nanoparticle-Based Tandem Semiconductor Units:
| ● | Validated Manufacturability at Scale: Successfully
validated the manufacturability of our substrates at both 25 cm² and 100 cm² scales, confirming the scalability of our nanoparticle
technology. |
| ● | Optimization of Plating Recipe for Second Junction Units:
Developed and optimized a plating recipe for the semiconductor unit in the second junction, resulting in best-in-class devices demonstrating
photovoltages greater than 0.9 volts and short-circuit current densities exceeding 20 mA/cm². |
| ● | E nhanced Photovoltage Achievement: Developed manufacturing
recipes for the first and second semiconductor junctions, achieving combined photovoltages exceeding 1.8 volts. This surpasses the required
photovoltage for water-splitting by 1.5 times, ensuring optimal performance and efficiency despite potential voltage losses. |
| ● | Demonstrated Stability Under Accelerated Conditions:
Showed stable performance of the nanoparticle semiconductor units for over 100 hours under continuous 1 sun illumination at elevated
temperatures, replicating accelerated degradation conditions. This stability indicates potential for significantly longer operational
lifespans under standard conditions. |
| ● | Acquisition and Utilization of High-Throughput Catalyst
Coating Equipment: Acquired high-throughput catalyst coating equipment capable of coating hydrogen and oxygen evolution catalysts
over areas up to 1000 cm². Further using this equipment, and in collaboration with Heraeus, we demonstrated that the catalysts could
achieve a combined overpotential of 350 mV or lower at 10 mA/cm², enabling hydrogen and oxygen generation at potentials below 1.6
volts, leaving room for enhanced performance as the semiconductor units can supply 1.8 volts. |
| ● | Collaboration with COTEC for Scale-Up: Collaborating
with COTEC to scale up and enable high-throughput production of nanoparticle semiconductor units, aiming to replicate lab-scale performance
at a larger scale (greater than or equal to 100cm2) with a manufacturing yield greater than 90%. |
Thin-Film PV Cell-Based Hydrogen Modules:
| ● | Development of a Transformative Hydrogen Module Design:
Successfully developed a hydrogen module design that adapts a commercial thin-film photovoltaic (PV) module into a hydrogen module without
altering the existing manufacturing process. This innovation allows the same manufacturing tools to produce both PV and hydrogen modules,
streamlining the transition and reducing costs. |
| ● | Successful Fabrication of Hydrogen Modules: In collaboration
with CTF Solar, we successfully implemented the hydrogen module design and fabricated hydrogen modules with a 100 cm² surface area. |
| ● | Achieved Stable Operation and High Solar-to-Hydrogen Efficiency:
Developed stabilization schemes and catalyst integration strategies that enable these hydrogen modules to operate stably at solar-to-hydrogen
conversion efficiencies exceeding 10%. |
Additional accomplishments that span both nanoparticle-based and thin
film-based hydrogen modules include:
| ● | Advanced Housing Unit: Developed a housing unit design,
in collaboration with SunHydrogen consultants Prof. Nirala Singh, Prof. Kazunari Domen, Dr. Hiroshi Nishiyama, and Dr. Taro Yamada, for
both nanoparticle and thin-film modules. This design enables the production and separation of hydrogen (H₂) and oxygen (O₂)
without the need for expensive ion exchange membranes, reducing costs and simplifying the manufacturing process. |
| ● | Joint Validation and Testing: Our nanoparticle-based
semiconductor units and thin-film-based hydrogen modules are currently undergoing testing and validation at Honda R&D labs in Japan.
Additionally, our collaborators in the NanoPEC project are focused on validating the long-term stability of the nanoparticle semiconductor
units. These rigorous evaluations are essential to verify performance, stability, and scalability, ensuring our technologies meet the
highest standards for commercialization. |
Led
by Dr. Nirala Singh, one of the lead inventors on SunHydrogen Patent No. 9,593,053B1, the University of Michigan team is focused on understanding
the hydrogen collection efficiency and optimizing and testing potential oxygen evolution and hydrogen evolution electrocatalysts to accelerate
scaleup and increased efficiency of photoelectrochemically active heterostructures.
In the past year, they identified
the most promising configurations to minimize the significant energy losses and produce hydrogen at a high rate. They further tested these
configurations in the Generator Housing for different system areas with oxygen evolution and hydrogen evolution catalysts and measured
the collection efficiency of hydrogen following its production. The effect of different pre-treatment conditions on the activity and stability
of the hydrogen evolution catalyst and oxygen evolution catalyst was also evaluated for continuous operation in a three-electrode setup
and the treatment variables with the most significant contribution to activity and stability identified. The overall voltage required
for water splitting using these optimized conditions has been lowered from that of last year. University of Michigan is developing strategies
to further improve the stability of the oxygen evolution electrocatalyst as well as alternate methods to deposit the electrocatalysts
on different supports.
University of Michigan demonstrated
the use of the system in the Generator Housing without membranes while maintaining a high faradaic efficiency and purity of hydrogen generation.
This system was evaluated using the gas collection system developed in the previous year. University of Michigan demonstrated the high
purity and faradaic efficiency under various Generator Housing orientations (e.g., angle) and temperatures. The elimination of the membrane
can assist with reducing capital and processing costs. Potential causes of high series resistance have been identified and addressed to
improve the overall efficiency of the system. University of Michigan also evaluated the performance of the system in the Generator Housing
under different flow conditions and electrolyte compositions to determine the effect on performance and collection efficiency. University
of Michigan is developing strategies to further mitigate the series resistance in the device.
Outside
of our central research and development hub in Iowa and our work with the University of Iowa and the University of Michigan, we have further
expanded our industrial partnerships across the U.S., Germany, South Korea, and Japan.
Our
current industrial partners and vendors include: Honda R&D Co. Ltd; CTF Solar GmbH; the National Renewable Energy Laboratory (NREL);
COTEC Corp.; Geomatec; Project NanoPEC; Schmid Group; Heraeus; and Strategic Analysis. By diversifying our commercialization strategy
in this way, we have formed relationships with industrial partners who are specialized in individual components of our technology such
as electroplating, substrate processing and catalyst/membrane integration, and techno-economics.
Honda R&D Co. Ltd
is our housing unit and balance of system partner.
With CTF Solar, we are
working to integrate their commercial PV cell module design into our technology for green hydrogen production.
The National Renewable
Energy Laboratory (NREL) is our thin film PV cell design partner.
COTEC is a production
partner for our PAH (Photoelectrosynthetically Active Heterostructures) nanoparticle technology, and Geomatec is a PAH substrate vendor.
Project NanoPEC has brought us together with a
group of six partners at the cutting edge of industry and science in Germany working to accelerate the commercialization of our technology.
These partners include the Fraunhofer Center for Silicon Photovoltaics, WAVELABS Solar Metrology Systems GmbH,
ECH Elektrochemie Halle GmbH, Zahner-Elektrik,
Helmholtz-Zentrum Berlin, and SCHMID Group. SCHMID Group is an additional manufacturing
partner.
Efforts on our hydrogen reactor design are led
by consultants Prof. Kazunari Domen, Dr. Hiroshi Nishiyama, Dr. Taro Yamada, and Prof. Nirala Singh.
We are working with Heraeus as our vendor for catalyst
optimization, and lastly, we are working with Strategic Analysis to conduct robust techno-economic analysis of our process.
Finally, while we remain dedicated to our primary
goal of developing our technology to commercialization, we are also passionate about furthering the renewable hydrogen ecosystem through
investment in, and acquisition of, complementary hydrogen technologies.
SunHydrogen
is an investor in Norway-based TECO 2030. With their zero-emission PEM hydrogen fuel cells stacks and modules, TECO
2030 is accelerating the transition to clean energy in the maritime and heavy-duty transportation sectors, and has formed strong relationships
with world-leading companies in the fuel cell industry in the process. Their longtime development partner AVL is the world's largest independent
company for the development, simulation and testing of powertrain systems. TECO 2030 is also partnered with thyssenkrupp Automation Engineering,
which holds over 100 years of fuel cell experience and €34 billion in revenue in 2021.
Every
day in the US, hundreds of thousands of diesel-powered trucks travel through routes with abundant land and sun. Our SunHydrogen panels
along and around these highways, producing green hydrogen at and near refueling sites, would potentially eliminate the need to transport
hydrogen fuel over long distances, lowering the high costs and hydrogen losses that would otherwise happen in long-distance transport.
In the future, we believe our green hydrogen panels along major trucking routes worldwide, together with the proliferation of TECO 2030's
hydrogen fuel cell technology, can make a significant mark on the industry.
Market Opportunity
Hydrogen generation is projected
to become a $1 trillion per year market by 2050 (Source: Goldman Sachs, Carbonomics: The clean hydrogen revolution). Current fossil
fuels can’t sustain future energy requirements environmentally or economically, and hydrogen fuel technologies are being adopted
across all sectors as the world moves toward renewable alternatives.
Over 140 countries have set
goals to achieve net-zero emissions by 2050, and as governments are looking to clean energy sources like hydrogen to help them meet their
targets (Source: United Nations, Net Zero Coalition). It is estimated that nearly 25% of global energy will come from clean hydrogen
alone by 2050 (Source: Goldman Sachs, Green Hydrogen: The next transformational driver of the Utilities industry).
Over 1,000 green hydrogen
production demonstration projects have been announced around the world, and policy leaders have put forth ambitious strategies to utilize
hydrogen and fuel cell technologies across all sectors of the economy including transportation, feedstock and industrial heat use (Source:
The Hydrogen Council and McKinsey & Company, Hydrogen Insights 2023).
Existing Market Growth
As supply chain challenges
and geopolitical conflicts continue to affect fuel prices globally, the hydrogen market is rallying support from consumers and governments
alike.
In
August 2022, The Inflation Reduction Act, which allotted $369 billion to renewable energy and climate projects, was signed into law in
the US. “Among its features, the law has a 10-year extension of solar and wind tax credits and incentives to support new technology,
with hydrogen and energy storage set to be the greatest beneficiaries,” according to Morningstar’s chief US market strategist
Dave Sekera (Source: Markets Insider, Clean energy stocks are set to be the big winners of the sweeping Inflation Reduction Act just
signed by Biden, Morningstar says). Specifically, the Act included a tax credit that will award up to $3/kg for low carbon
hydrogen, with exact credit amounts to be determined by calculating a given project’s greenhouse gas emissions (Source: S&P
Global, Hydrogen tax credits preserved in new US Inflation Reduction Act).
Since
the passage of the Inflation Reduction Act, the US has seen additional promising legislation in favor of the adoption of hydrogen as a
replacement for fossil fuels. Most recently, the US Department of Energy released its intent to invest up to an additional $1 billion
to support the Regional Clean Hydrogen Hubs program, an already-$7 billion initiative to create six to ten regional clean hydrogen hubs
across the country (Source: DOE, Biden-Harris Administration to Jumpstart Clean Hydrogen Economy with New Initiative to Provide Market
Certainty and Unlock Private Investment). According to the DOE, America’s growing hydrogen economy has the potential to add
100,000 net new direct and indirect jobs by 2030 (Source: DOE, DOE’s Pathways to Commercial Liftoff: Clean Hydrogen report).
An additional factor driving
the global hydrogen market is the need to reduce sulfur content in petroleum products. U.S. federal and state governments have adopted
various programs, including the Tier 3 program, to reduce the sulfur content in gasoline, motor oil and diesel. Particularly, there is
a growing demand for petroleum products from developing countries. Hydrogen is used in various refining processes including hydrocracking
and hydrodesulfurization to crack bigger molecules into lighter ones and produce more usable products.
For all these reasons and
more, we believe our renewable hydrogen-producing technology possesses significant early market opportunity, especially as innovation
and infrastructure continue to develop.
Hydrogen Mobility
Industry is projected to drive
the majority of clean hydrogen uptake until 2030 followed by a wider uptake in new applications by 2050, according to a 2024 report by
McKinsey & Company (Source: McKinsey & Company, Global Energy Perspective 2023: Hydrogen outlook). Specifically, the mobility
sector is expected to account for a considerable portion of the demand for clean hydrogen.
Hydrogen-powered
trucks and hydrogen refueling stations present a variety of cost, scalability, and sustainability-related benefits over battery power.
Namely, hydrogen-fueled trucks can refuel faster and carry a lower weight penalty than battery-powered trucks because tanks weigh considerably
less than batteries. At scale, the infrastructure is less costly to create than e-truck charging infrastructure because it does not require
grid upgrades and has a smaller carbon footprint. Faster refueling speed also means the hydrogen infrastructure can be used by many more
trucks (Source: McKinsey & Company, Unlocking hydrogen’s power for long-haul freight transport).
Additionally,
the applications for hydrogen mobility stretch far beyond road travel vehicles:
At
one Amazon fulfillment center in Aurora, Colorado, a Plug Power electrolyzer system is already helping produce hydrogen to fuel more than
225 hydrogen fuel cell-powered forklift trucks at the site (Source: Utility Dive, Amazon to generate hydrogen on-site with Plug Power’s
electrolyzer system).
In
Norway, Norwegian state-owned technology company Enova has awarded approximately $112 million in grants to commercialize 15 hydrogen and
ammonia-fueled maritime vessels (Source: Riviera Maritime Media, Norway goes big on hydrogen and ammonia-fuelled ships).
Dutch
airline KLM has teamed up with ZeroAvia to develop a liquid hydrogen-powered turboprop aircraft, and they have raised over $300 million
from Amazon, Airbus, and British Airways to do so (Source: The Next Web, KLM targets liquid hydrogen plane takeoff in 2026).
While infrastructure scale-up and technology advancements
are still needed to meet demand, it’s clear that momentum is rapidly building among innovators, government agencies, and industry
stakeholders alike.
Our
Technology
Technology for Making Renewable Hydrogen
from Sunlight and Water
Powered by solar energy, our technology utilizes two innovative approaches
to produce renewable hydrogen from water, leaving behind only clean oxygen as a byproduct:
| ● | Nanoparticle-Based Photoelectrosynthetically Active Heterostructures
(PAH): Our microscopic PAH nanoparticles function like tiny machines that mimic the natural process of photosynthesis within a plant
cell. Composed of multiple layers, these nanoparticles enable solar-powered electrolysis to occur at the molecular level, splitting water
to extract hydrogen as a clean energy source. This nanoparticle-based system offers high fault tolerance and superior solar-to-hydrogen
efficiencies at a low cost, making it an economically viable and scalable solution for green hydrogen production. |
| ● | Thin-Film PV Cell-Based Hydrogen Modules: In parallel, we
are also developing hydrogen modules in collaboration with CTF Solar, using commercially available thin-film photovoltaic (PV) technology.
These modules are re-engineered with our proprietary hydrogen module design to perform solar water splitting without altering the existing
PV manufacturing process. This approach leverages mature manufacturing platforms, allowing for faster market entry while still enabling
cost-effective and scalable hydrogen production. |
By advancing both nanoparticle and thin-film PV cell technologies,
we are strategically positioned to accelerate the production of green hydrogen, providing versatile and scalable solutions to meet global
clean energy needs.
Water Splitting
In the process of splitting
a water molecule, input energy is transferred into the chemical bonds. Essentially, manufactured hydrogen serves as a carrier or battery-like
storage of the input energy. If the input energy is from fossil fuels, such as oil and gas, then carbon fossil fuel energy is simply transferred
into hydrogen. If the input energy is renewable, such as solar or wind, then new and clean energy is stored in hydrogen.
While the concept of water
splitting is very appealing, the following industry-wide challenges must be addressed for renewable hydrogen to be commercially viable:
| ● | Energy
Inefficiency — Since hydrogen is an energy carrier, the most energy it can store is 100% of the input energy. However,
conventional electrolysis methods lose much of the input energy in system components, wires and electrodes resulting in only a small
portion of electricity making it into the hydrogen molecules. This translates to high production cost and is the fundamental problem
with water splitting for hydrogen production. We intend to address this problem with our low-cost and energy-efficient nanoparticle technology. |
| ● | Need
for Clean Water — Conventional electrolysis requires highly purified clean water to prevent fouling of system components.
This prevents current technology from using large quantities of available water from oceans, rivers, industrial waste and municipal waste
as feedstock. We are currently working with acidic or alkaline water, as well as wastewater, to produce renewable hydrogen through our
nanoparticle technology. |
Technology
Water electrolysis in its simplest form is the
transfer of “input electrons” in the following chemical reactions:
| ● | Cathode
(reduction): 2H2O + 2e- +2 + 2OH- |
| ● | Anode
(oxidation): 4OH- 2 + 2H2O + 4 e- |
From these equations, one
can deduce that if every input electron (e-) is put to work and not lost, then a maximum amount of input electrons (i.e.
energy) is transferred and stored in the hydrogen molecules (H2). Additionally, if there were a very high number of cathode
and anode reaction areas within a given volume of water, then a very high number of these reactions could happen simultaneously throughout
the medium to split each water molecule into hydrogen wherever electrons are available.
SunHydrogen Panel™
Since our particles are
intended to mimic the natural process of photosynthesis, directly producing hydrogen and oxygen without the need for costly intermediate
power conversions, they can be housed in very low-cost reactors. To facilitate the commercial use of our self-contained particle technology,
we are developing a modular system that will enable the onsite daily production and storage of hydrogen for any-time use in electricity
generation.
We refer to our potential product
as the SunHydrogen Panel which is comprised of the following components:
| ● | Substrate: The
base material, typically glass coated with a thin layer of transparent conducting surface. |
| ● | Semiconductor:
Materials that have properties essential for photovoltaic energy conversion. |
| ● | Current Collector:
Utilized for the deposition of catalysts. |
| ● | Insulator: Materials
to neutralize the defects and pinholes and to stabilize semiconductors and substrates. |
| ● | Cathode: Equipped
with a Hydrogen Evolution Reaction (HER) catalyst responsible for hydrogen production. |
| ● | Anode: Outfitted
with an Oxygen Evolution Reaction (OER) catalyst that facilitates oxygen production. |
| ● | PV Cell: Denotes
a singular Photovoltaic (PV) cell, a basic unit that converts light into electrical energy. |
| ● | Hydrogen Sub-module:
Constitutes the minimum assembly of PV cells interconnected electrically and paired with catalysts to produce hydrogen and oxygen. |
| ● | Hydrogen Module:
A composite of several Hydrogen Sub-modules seamlessly integrated yet electrically separate, all set on a singular substrate for
efficient scaling and fault tolerance. |
| ● | Housing Unit:
Designed with end plates that feature flow field channels to streamline water flow and facilitate the separation of hydrogen and oxygen. |
| ● | Hydrogen Reactor:
A system that encompasses both the Hydrogen Module and its Housing, forming a complete unit for hydrogen generation. |
| ● | Hydrogen Panel: Comprises
one or more Hydrogen Reactors arranged together, forming an installation-ready unit that includes necessary ancillary components like
piping, as well as systems for hydrogen collection and water recirculation. |
| ● | Hydrogen Array: A
term that describes an aggregation of Hydrogen Panels organized to meet a specific hydrogen production goal, with capacities that can
range from 1 kW to 1 MW, or even as high as 1 GW. |
In addition to our sponsored
research agreements with the University of Iowa and University of Michigan, we are working with a growing group of specialized industrial
partners to help commercialize our renewable hydrogen panels that use sunlight and water to generate hydrogen. Our current industrial
partners include: Honda R&D Co. Ltd; CTF Solar GmbH; the National Renewable Energy Laboratory (NREL); COTEC Corp.; Geomatec; Project
NanoPEC; Schmid Group; the University of Tokyo; Heraeus; and Strategic Analysis.
Intellectual Property
On November 14, 2011, we
filed a provisional application with the U.S. Patent and Trademark Office to protect the intellectual property rights for “Photoelectrosynthetically
Active Heterostructures” A year later on November 14, 2012, we filed a non-provisional application claiming priority to the provisional
application. On March 14, 2017, a first patent covering the structural design of Photoelectrosynthetically Active Heterostructures (PAH)
was granted as United States Patent No. 9,593,053B1. A divisional application claiming priority to the foregoing applications was filed,
and on April 3, 2018, a second patent covering the method for manufacturing PAH was granted as United States Patent No. 9,593,053B2. These
patents protect the Company’s proprietary design and manufacturing method of a self-contained solar-to-hydrogen device made up of
billions of solar-powered water-splitting nanoparticles, per square centimeter. These nanoparticles are separated by a protective coating
that prevents corrosion during extended periods of hydrogen production. The aim of producing these nanoparticles is to achieve high solar
-to-hydrogen conversion efficiency at low cost. These patents expire on November 14, 2032.
An important aspect of the
patented technology referred to in the preceding paragraph is the integrated structures of high-density arrays of nano-sized PV cells
as part of hydrogen production nanoparticles. The technology enables manufacturing of ultra-thin sheets for solar hydrogen production,
requiring substantially less material as compared to conventional PV cells used in rooftop power applications.
On March 21, 2014, we jointly
filed a provisional application with the University of California, Santa Barbara for the “Multi-junction artificial photosynthetic
cell with enhanced photovoltages.” Thereafter, we filed a non-provisional application on March 16, 2015 and a corresponding PCT
Application on March 17, 2015. These applications cover our semiconductor designs to enhance the photovoltages of the nano-sized PV cells
in the PAH structures. The semiconductor designs stacking multiple junctions inside the PAH structures would be an efficient and economical
solution for the photovoltaic and the photoelectrochemical industries. Patents were granted in Australia in April of 2018, China and Europe
in March of 2019, and in the U.S. as United States Patent No. 10,100,415 in October of 2018. The last patent from this international application
was granted in India in October 2022. This patent expires on October 21, 2036.
On September 26, 2016, we
filed jointly with the University of Iowa a provisional application for “Integrated Membrane Solar Fuel Production Assembly”
to protect the intellectual property for our generator housing system that safely separates oxygen and hydrogen in the water-splitting
process without sacrificing efficiency. This device houses the water, the solar particles/cells and is designed with inlets and outlets
for water and gases. Utilizing a special architecture that integrates membranes for separating the oxygen side from the hydrogen side,
proton transport is increased which is the key to safely increasing solar-to-hydrogen efficiency. On September 26, 2017, we filed a PCT
Application that was later nationalized in the U.S. on March 26, 2019. On April 15, 2024, after a thorough review of our corporate commercialization
plan, we made the decision to abandon the patent application. While the intellectual property was critical for the designs of the early
GEN I and GEN II inventions, as our process and system designs evolved, we determined that the IP no longer aligned with our future developments.
On August 7, 2024, we filed a provisional patent application covering
the design and manufacturing processes of fully integrated solar hydrogen modules, utilizing existing infrastructure from the photovoltaic
(PV) industry. The protected IP facilitates the immediate commercial production of these modules, accelerating their entry into the market
for rapid adoption.
Strategic Partners
We are currently engaged in
a sponsored research agreement with the University of Iowa. This term of the research agreement runs through October 2024 but may be extended
upon mutual agreement of the parties.
We are currently engaged
in a sponsored research agreement with the University of Michigan. This term of the research agreement runs through September 2024 but
may be extended upon mutual agreement of the parties.
We are currently engaged
in a technology collaboration agreement with COTEC. This term of the agreement runs through September 2024 and both parties are currently
continuing the collaboration while working to enter into a new collaboration agreement.
We are currently engaged
in a technology collaboration agreement with Project NanoPEC. This term of the agreement runs through June 2026 but may be extended upon
mutual agreement of the parties.
We are currently engaged
in a technology collaboration agreement with CTF Solar. This term of the agreement runs through January 2026 but may be extended upon
mutual agreement of the parties.
We are currently engaged
in a joint development agreement with Honda R&D Co. This term of the agreement runs through March 2026 but may be extended upon mutual
agreement of the parties.
We have also initiated a
research agreement with the National Renewable Energy Laboratory (NREL). This research agreement runs through October 2025 but may be
extended upon mutual agreement of the parties.
Additionally, we are engaged
in an ongoing consulting contract with Strategic Analysis, Inc. to aid in further reducing our system cost through techno-economic research
and evaluation.
Competition
Currently, most hydrogen
is produced by steam reforming of natural gas or methane. This production technology dominates due to easy availability and low prices
of natural gas. Partial oxidation of petroleum oil is second in production capacity after steam reforming of natural gas. The third largest
production technology in terms of production capacity is steam gasification of coal. Key players in the traditional hydrogen production
industry include Linde, Air Liquide, Air Products, Praxair, and more.
At this time, we view our primary competition
as companies that have developed or are currently developing renewable hydrogen production technology. Green or renewable hydrogen can
be produced through electrolyzers if the electrolyzers are powered by renewable energy sources, such as solar or wind. Some of these companies
include:
Plug Power: Plug Power (Stock symbol: PLUG) is engaged in the development of hydrogen fuel cell systems that replace conventional
batteries in equipment and vehicles powered by electricity. The company is currently building green hydrogen plants to produce at least
70 tons of liquid green hydrogen daily by the end of 2022 and 500 tons daily by 2025.
NEL Hydrogen: NEL Hydrogen (Stock symbol: NLLSF) delivers solutions to produce, store, and distribute hydrogen from renewable energy.
The company’s hydrogen solutions cover the entire value chain from hydrogen production technologies to hydrogen fueling stations,
enabling industries to transition to green hydrogen.
Fusion Fuel: Fusion Fuel (Stock symbol: HTOO) has developed a modular solar to hydrogen solution, combining proven solar concentration
technology with a proprietary micro-electrolyzer that allows it to produce zero-emissions green hydrogen at highly competitive costs.
The company sells its HEVO-Solar technology to customers interested in producing their own green hydrogen. It also develops company-owned
green hydrogen farms.
ITM Power: ITM Power (Stock symbol: ITMPF) designs, manufactures, and integrates electrolyzers based on proton exchange membrane
technology to produce green hydrogen using renewable electricity and tap water. ITM Power works with strategic partners including Linde,
Shell, Snam, Hyundai, and Honda to scale its impact and industrial reach.
McPhy: McPhy (Stock symbol: MCPHY) specializes in the design, production and integration of high pressure alkaline electrolyzers
and hydrogen stations. McPhy has five development, engineering and production sites in France, Italy, and Germany, and it is backed by
solid and constantly-evolving European industrial foundations.
If not powered by renewable
sources, electrolyzers require external electricity most likely created by coal, gas or oil. We believe that our process when fully developed
may potentially offer a competitive advantage as we anticipate it will be fully renewable and utilize no external power other than the
sun. However, it should be noted that the renewable hydrogen market is rich with competitors, like the companies mentioned above, who
have already successfully commercialized green hydrogen production technologies. We anticipate that existing leaders will continue to
hone the efficiency of their products and drive down cost of green hydrogen per kilogram, creating a more competitive, challenging environment
for emerging, not-yet-commercialized technologies such as our own.
Corporate Information
We were incorporated in the
State of Nevada on February 18, 2009. Our executive offices are located at 2500 Crosspark Road, Coralville IA 52241.
Employees
As of September 12, 2024,
we have 7 full-time employees and several consultants. We have not experienced any work stoppages and we consider relations with our employees
and consultants to be good. Our research and development work is performed at our Coralville, Iowa laboratory, as well as with the University
of Iowa and the University of Michigan through sponsored research agreements, and in collaboration with our industrial partners.
Item 1A. Risk Factors.
Risks related to our business and industry
Our limited operating history does not afford
investors a sufficient history on which to base an investment decision.
We were formed in February
2009 and are currently developing a new technology that has not yet gained market acceptance. There can be no assurance that we will ever
operate profitably or that we will have adequate working capital to meet our obligations as they become due.
Investors must consider the
risks and difficulties frequently encountered by early-stage companies, particularly in rapidly evolving markets. Such risks include the
following:
|
● |
competition; |
|
|
|
|
● |
need for acceptance of products; |
|
|
|
|
● |
ability to continue to develop and extend brand identity; |
|
|
|
|
● |
ability to anticipate and adapt to a competitive market; |
|
|
|
|
● |
ability to effectively manage rapidly expanding operations; |
|
|
|
|
● |
amount and timing of operating costs and capital expenditures relating to expansion of our business, operations, and infrastructure; and |
|
|
|
|
● |
dependence upon key personnel. |
We cannot be certain that
our business strategy will be successful or that we will successfully address these risks. In the event that we do not successfully address
these risks, our business, prospects, financial condition, and results of operations could be materially and adversely affected, and we
may have to curtail our business.
We have a history of losses and have never
realized revenues to date. We expect to continue to incur losses and no assurance can be given that we will realize revenues. Accordingly,
we may never achieve and sustain profitability.
As of June 30, 2024, we have
an accumulated deficit of $91,852,243. For the year ended June 30, 2024, we incurred a net loss of $9,881,203. We expect to incur net
losses until we are able to realize revenues to fund our continuing operations. We may fail to achieve any or significant revenues from
sales or achieve or sustain profitability. Accordingly, we may never be profitable or be able to maintain profitability.
We have historically raised
funds through various capital raising transactions. We will require additional funds in the future to fund our business plans, either
through additional equity or debt financings or collaborative agreements or from other sources. We have no commitments to obtain such
additional financing, and we may not be able to obtain any such additional financing on terms favorable to us, or at all. In the event
we are unable to obtain additional financing, we may be unable to implement our business plan. Even with such financing, we have a history
of operating losses and there can be no assurance that we will ever become profitable.
We may be unable to manage our growth or
implement our expansion strategy.
We may not be able to develop
our product or implement the other features of our business strategy at the rate or to the extent presently planned. Our projected growth
will place a significant strain on our administrative, operational and financial resources. If we are unable to successfully manage our
future growth, establish and continue to upgrade our operating and financial control systems, recruit and hire necessary personnel or
effectively manage unexpected expansion difficulties, our financial condition and results of operations could be materially and adversely
affected.
We may not be able to successfully develop
and commercialize our technologies which would result in continued losses and may require us to curtail or cease operations.
We are currently working to
scale the lab-scale prototypes of our nanoparticle technology to larger, commercial-scale prototypes. However, we have not completed a
large-scale commercial prototype of our technology and are uncertain at this time when completion of a commercial scale prototype will
occur. Although the lab scale prototype demonstrates the viability of our technology, we may be unable to commercialize our technology.
Our revenues will be dependent upon acceptance
of our products by the market, the failure of which would cause us to curtail or cease operations.
We believe that virtually
all of our revenues will come from the sale or license of our products. As a result, we will continue to incur substantial operating losses
until such time as we are able to develop our product and generate revenues from the sale or license of our products. There can be no
assurance that businesses and customers will adopt our technology and products, or that businesses and prospective customers will agree
to pay for or license our products. Our technology and product, when fully developed, may not gain market acceptance due to various factors
such as not enough cost savings between our method of producing hydrogen and other more conventional methods. If that occurs,, our financial
condition and results of operations will be materially and adversely affected.
We anticipate that we will face intense
competition, and many of our competitors have substantially greater resources than we do.
We operate in a competitive
environment that is characterized by price fluctuation and technological change. We anticipate that we will compete with major international
and domestic companies. Some of our current and future potential competitors may have greater market recognition and customer bases, longer
operating histories and substantially greater financial, technical, marketing, distribution, purchasing, manufacturing, personnel and
other resources than we do. In addition, competitors may be developing similar technologies with a cost similar to, or lower than, our
projected costs. As a result, they may be able to respond more quickly to changing customer demands or to devote greater resources to
the development, promotion and sales of solar and solar-related products than we can.
Our business plan relies on
sales of our products based on either a demand for truly renewable clean hydrogen or economically produced clean hydrogen. If we fail
to compete successfully, our business would suffer and we may lose or be unable to gain market share. Neither the demand for our product
nor our ability to manufacture at commercial scale have yet been proven.
Because our industry is highly competitive
and has low barriers to entry, we may lose market share to larger companies that are better equipped to weather a deterioration in market
conditions due to increased competition.
We believe that our ability
to compete depends in part on a number of factors outside of our control, including:
|
● |
the ability of our competitors to hire, retain and motivate qualified personnel; |
|
|
|
|
● |
the ownership by competitors of proprietary tools to customize systems to the needs of a particular customer; |
|
|
|
|
● |
the price at which others offer comparable services and equipment; |
|
|
|
|
● |
the extent of our competitors’ responsiveness to customer needs; and |
|
|
|
|
● |
installation technology. |
Currently, competing methods
of hydrogen production include steam reforming of natural gas or methane, which dominates due to its easy availability and low price;
partial oxidation of petroleum oil; steam gasification of coal; and electrolyzers powered by solar or wind energy. There can be no assurance
that we will be able to compete successfully against current and future competitors. If we are unable to compete effectively, or if competition
results in a deterioration of market conditions, our business and results of operations would be adversely affected.
Our business depends on proprietary technology
that we may not be able to protect and may infringe on the intellectual property rights of others.
Our success will depend, in
part, on our technology’s commercial viability and on the strength of our intellectual property rights. We currently hold patents
in the US, China, Australia, and Europe but still have several patents pending in multiple countries. There is no guarantee the
pending patents will be granted. In addition, any agreements we enter into with our employees, consultants, advisors, customers and strategic
partners will contain restrictions on the disclosure and use of trade secrets, inventions and confidential information relating to our
technology may not provide meaningful protection in the event of unauthorized use or disclosure.
Third parties may assert that
our technology, or the products we, our customers or partners commercialize using our technology, infringes upon their proprietary rights.
We have yet to complete an infringement analysis and, even if such an analysis were available at the current time, it is virtually impossible
for us to be certain that no infringement exists, particularly in our case where our products have not yet been fully developed.
We may need to acquire licenses
from third parties in order to avoid infringement. Any required license may not be available to us on acceptable terms, or at all.
We could incur substantial
costs in defending ourselves in suits brought against us for alleged infringement of another party’s intellectual property rights
as well as in enforcing our rights against others, and if we are found to infringe, the manufacture, sale and use of our or our customers’
or partners’ products could be enjoined. Any claims against us, with or without merit, would likely be time-consuming, requiring
our management team to dedicate substantial time to addressing the issues presented. Furthermore, the parties bringing claims may have
greater resources than we do.
We do not maintain theft or casualty insurance
and only maintain modest liability and property insurance coverage and therefore, we could incur losses as a result of an uninsured loss.
We do not maintain theft,
casualty insurance, or property insurance coverage. We may incur uninsured liabilities and losses as a result of the conduct of our business.
Any such uninsured or insured loss or liability could have a material adverse effect on our results of operations.
If we lose key employees and consultants
or are unable to attract or retain qualified personnel, our business could suffer.
Our success is highly dependent
on our ability to attract and retain qualified scientific, engineering and management personnel. We are highly dependent on our Chief
Science Officer, Dr. Syed Mubeen, our development team in Iowa and our industrial partners and vendors. There can be no assurance
that they will remain associated with us. Our management’s efforts will be critical to us as we continue to develop our technology
and as we attempt to transition from a development stage company to a company with commercialized products and services. If we were to
lose Dr. Mubeen, one of our development partners, any other key employees or consultants, we may experience difficulties in competing
effectively, developing our technology and implementing our business strategies.
The loss of strategic alliances used in
the development of our products and technology could impede our ability to complete our product and result in a material adverse effect
causing the business to suffer.
We pursue strategic alliances
with other companies in areas where collaboration can produce technological and industry advancement. For example, we have entered into
a sponsored research agreement with the University of Michigan which, which was extended through September 30, 2024. If we are unable
to extend the terms of this agreement, or any of our other agreements with our partners as described in this report, we could suffer delays
in product development or other operational difficulties which could have a material adverse effect on our results of operations.
Risks relating to our common stock
There is a limited trading market for our
common stock.
Our common stock is not listed
on any national securities exchange. Accordingly, investors may find it more difficult to buy and sell our shares than if our common stock
was traded on an exchange. Although our common stock is quoted on the OTCQB, it is an unorganized, inter-dealer, over-the-counter market
which provides significantly less liquidity than the Nasdaq Capital Market or other national securities exchange. Further, there is limited
trading in our common stock. These factors may have an adverse impact on the trading and price of our common stock.
Our common stock could be subject to extreme
volatility.
The trading price of our common
stock may be affected by a number of factors, including events described in the risk factors set forth in this report, as well as our
operating results, financial condition and other events or factors. In addition to the uncertainties relating to future operating performance
and the profitability of operations, factors such as variations in interim financial results or various, as yet unpredictable, factors,
many of which are beyond our control, may have a negative effect on the market price of our common stock. In recent years, broad stock
market indices, in general, and smaller capitalization companies, in particular, have experienced substantial price fluctuations. In a
volatile market, we may experience wide fluctuations in the market price of our common stock and wide bid-ask spreads. These fluctuations
may have a negative effect on the market price of our common stock. In addition, the securities market has, from time to time, experienced
significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations
may also materially and adversely affect the market price of our common stock.
We anticipate that our issuance of common
stock upon conversion of Series C Preferred Shares will result in dilution to our stockholders.
As of June 30, 2024, we have
outstanding shares of redeemable Series C Preferred Stock with an aggregate stated value of $885,100 that are convertible into common
stock at a fixed conversion price of $0.00095 (see Note 3 to the financial statements included in this report). We anticipate that our
issuance of common stock upon conversion of outstanding preferred shares will result in dilution to holders of our common stock, which
may have a negative effect on the price of our common stock. In addition, as of June 30, 2024, we have outstanding warrants to purchase
78,095,239 shares of common stock and options to purchase 266,894,499 shares of common stock, and our issuance of shares of common stock
upon exercise of outstanding warrants or options may result in additional dilution to our stockholders.
We have never paid common stock dividends
and have no plans to pay dividends in the future, as a result our common stock may be less valuable because a return on an investor’s
investment will only occur if our stock price appreciates.
Holders of shares of our common
stock are entitled to receive such dividends as may be declared by our Board of Directors. To date, we have paid no cash dividends on
our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain
future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our common stock will be
in the form of appreciation in the market value of our shares of common stock, which may not occur.
Our common stock is subject to the SEC’s
penny stock rules.
Unless our common stock is
listed on a national securities exchange, including the Nasdaq Capital Market, or we have stockholders’ equity of $5,000,000 or
less and our common stock has a market price per share of less than $5.00, transactions in our common stock will be subject to the SEC’s
“penny stock” rules. If our common stock remains subject to the “penny stock” rules promulgated under the Securities
Exchange Act of 1934, broker-dealers may find it difficult to effectuate customer transactions and trading activity in our securities
may be adversely affected.
In accordance with these rules,
broker-dealers participating in transactions in low-priced securities must first deliver a risk disclosure document that describes the
risks associated with such stocks, the broker-dealer’s duties in selling the stock, the customer’s rights and remedies and
certain market and other information. Furthermore, the broker-dealer must make a suitability determination approving the customer for
low-priced stock transactions based on the customer’s financial situation, investment experience and objectives. Broker-dealers
must also disclose these restrictions in writing to the customer, obtain specific written consent from the customer, and provide monthly
account statements to the customer. The effect of these restrictions will probably decrease the willingness of broker-dealers to make
a market in our common stock, decrease liquidity of our common stock and increase transaction costs for sales and purchases of our common
stock as compared to other securities. Our management is aware of the abuses that have occurred historically in the penny stock market.
This may make it more difficult
for investors to dispose of our common stock and cause a decline in the market value of our stock.
Our articles of incorporation allow for
our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights
of the holders of our common stock.
Our board of directors has
the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to
issue up to 5,000,000 shares of our preferred stock without further stockholder approval. As a result, our board of directors could authorize
the issuance of a series of preferred stock that would grant to holders of preferred stock the right to our assets upon liquidation, or
the right to receive dividend payments before dividends are distributed to the holders of common stock. In addition, our board of directors
could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible
into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.
Additional stock offerings in the future
may dilute then-existing shareholders’ percentage ownership of the Company.
Given our plans and expectations
that we will need additional capital, we anticipate that we will need to issue additional shares of common stock or securities convertible
or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. We anticipate
that our issuance of additional common stock or securities convertible into or exercisable into common stock in the future will dilute
the percentage ownership of then current stockholders.
Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity.
Not applicable.
Item 2. Properties.
Our principal office address
and independent laboratories are located at the BioVentures Center at 2500 Crosspark Rd., Coralville, IA 52241.
Item 3. Legal Proceedings.
We are not currently a party
to, nor is any of our property currently the subject of, any material legal proceedings.
Item 4. Mine Safety Disclosures.
Not Applicable.
PART II
Item 5. Market for Registrant’s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock is quoted
on the OTCQB under the symbol “HYSR.”
Common Stock
Our Articles of Incorporation,
as amended, authorizes the issuance of 10,000,000,000 shares of common stock, $0.001 par value per share and 5,000,000 shares of preferred
stock, par value $0.001 per share.
All outstanding shares of
common stock are of the same class and have equal rights and attributes. The holders of our common stock are entitled to one vote
per share on all matters submitted to a vote of our stockholders. All stockholders are entitled to share equally in dividends, if any,
as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders
of our common stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not
have cumulative or preemptive rights.
As of September 13, 2024 our
common stock was held by approximately 89 stockholders of record.
Dividend Policy
We have never declared or
paid any cash dividends on our common stock. We do not anticipate paying any cash dividends to stockholders in the foreseeable future.
In addition, any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent
upon our financial condition, results of operations, capital requirements, and such other factors as the Board of Directors deem relevant.
There are no restrictions in our articles of incorporation or bylaws that restrict us from declaring dividends.
Recent Sales of Unregistered Securities
None
Issuer Purchases of Equity Securities
None.
Item 6. [Reserved.]
Item 7. Management’s Discussion and Analysis
of Financial Conditions and Results of Operations.
Certain statements in “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” below, and elsewhere in this annual report, are not related
to historical results, and are forward-looking statements.
Forward-looking statements
present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly
to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance
or achievements expressed or implied by such forward-looking statements. Forward-looking statements frequently are accompanied by such
words such as “may,” “will,” “should,” “could,” “expects,” “plans,”
“intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential”
or “continue,” or the negative of such terms or other words and terms of similar meaning. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements,
or timeliness of such results. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such
forward-looking statements. We disclaim any obligation to publicly update these statements, or disclose any difference between actual
results and those reflected in these statements, except as may be required under applicable law
Subsequent written and oral
forward looking statements attributable to us or to persons acting in our behalf are expressly qualified in their entirety by the cautionary
statements and risk factors set forth below and elsewhere in this annual report, and in other reports filed by us with the SEC.
You should read the following
description of our financial condition and results of operations in conjunction with the financial statements and accompanying notes included
in this Annual Report beginning on page F-1.
Overview
SunHydrogen
is developing breakthrough technologies to make, store and use green hydrogen in a market that Goldman Sachs estimates to be worth $12
trillion by 2050. Our patented SunHydrogen Panel technology, currently in development, uses sunlight and any source of water to produce
low-cost green hydrogen. Similar to solar panels that produce electricity, our SunHydrogen Panels will produce green hydrogen. Our vision
is to become a major technology supplier in the new hydrogen economy. By developing, acquiring and partnering with other critical technologies,
we intend to enable a future of emission-free vehicles, ships, data centers, aircrafts and more.
Results of Operations for the Year Ended June
30, 2024 compared to the Year Ended June 30, 2023
Operating Expenses
For the year ended June 30, 2024, operating expenses
were $5,001,300 compared to $9,267,147, for the year ended June 30, 2023. Operating expenses consist primarily of research and development
expenses and general and administrative expenses incurred in connection with the operation of our business. The decrease of $4,265,847
in operating expenses was primarily due to, a decrease in non-cash stock compensation, a decrease in salary expenses, and a decrease in
research and development costs.
Other Income/(Expenses)
Other income and (expenses) for the year ended
June 30, 2024, were $(4,879,903) compared to $10,242,126 for the year ended June 30, 2023. The net decrease of $15,122,029 in other income
and (expenses) was the result of an increase in unrealized loss on related party equity investments of $7,349,102, an increase in dividend
expense of $85,940, an increase in realized loss of $169,389, a decrease in gain on derivative liability of $9,204,345, offset by an increase
in investment income of $864,115, an increase in capital gain on sale of vehicle of $55,166, an increase in realized gain on redemption
of marketable securities of $35,080, a decrease in loss on settlement of derivative liability of $664,627, and a decrease in interest
expense of $67,759.
Net Income (Loss)
For the year ended June 30,
2024, our net loss was $9,881,203, compared to net income of $974,979 for the year ended June 30, 2023. The majority of the decrease in
net income of $10,856,182, was related primarily to the decrease in gain on change of derivative liability, increase in unrealized loss
on investments, offset by the decrease in non-cash stock compensation.
Liquidity and Capital Resources
Liquidity is the ability of
a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing
basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts
payable and capital expenditures.
As of June 30, 2024, we had
a working capital surplus of $42,386,683, compared to a working capital surplus of $47,689,381 as of June 30, 2023. This decrease in working
capital surplus of $5,302,698 was primarily due to a decrease in marketable securities redeemed, and the change in fair value of a short-term
investment.
Cash flow used in operating
activities was $1,842,726 for the year ended June 30 2024, compared to $4,262,085 for the year ended June 30, 2023. The decrease of $2,419,359
in cash used by operating activities was primarily due to an increase in non-cash expense offset by a decrease in net loss. The Company
has had no revenues during the years ended June 30, 2024 and 2023.
Cash provided by investing
activities for the year ended June 30, 2024 was $2,920,237, compared to $11,101,386 for the year ended June 30, 2023. The decrease of
$8,181,149 in cash provided by investing activities was primarily due to a decrease in the net redemption of marketable securities offset
by a decrease in the purchase of related party investments, the purchase of a related party convertible note, and an increase in the redemption
of short-term investments in corporate securities.
Cash provided by financing
activities during the year ended June 30, 2024 was $781,295, compared to $2,665,203 for the year ended June 30, 2023. The decrease in
cash provided by financing activities was primarily due to a decrease in net proceeds from purchase agreements.
We have historically obtained
funding from investors, through private placements and registered offerings of equity and debt securities. Management believes that the
Company will be able to continue to raise funds through the sale of its securities to its existing shareholders and prospective new investors
which will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the Company to
continue to develop its core business. There can be no assurance that we will be able to continue raising the required capital for our
operations on terms and conditions that are acceptable to us, or at all. If we are unable to obtain sufficient funds, we may be forced
to curtail and/or cease our operation.
Off-Balance Sheet Arrangements
We do not have any off-balance
sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, result
of operations, liquidity or capital expenditures.
Critical Accounting Policies
Our discussion and analysis
of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of
contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property,
plant and equipment, intangible assets, deferred tax assets and fair value computation using the Binomial lattice valuation pricing model.
We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated
future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described
items, are reasonable.
Use of Estimates
In accordance with accounting
principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates
and assumptions relate to recording, useful lives and impairment of tangible and intangible assets, derivatives, accruals, income taxes,
stock-based compensation expense, binomial model inputs and other factors. Management believes it has exercised reasonable judgment in
deriving these estimates. Consequently, a change in conditions could affect these estimates.
Fair Value of Financial Instruments
Fair value of financial instruments,
requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate
that value. As of June 30, 2024 and 2023, the amounts reported for cash, accrued interest and other expenses, notes payables, and derivative
liability approximate the fair value because of their short maturities.
Recently Adopted Accounting Pronouncements
Management adopted recently
issued accounting pronouncements during the year ended June 30, 2024, as disclosed in the Notes to the financial statements included in
this report.
Item 7A. Quantitative and Qualitative Disclosure
About Market Risk.
Not required for a smaller
reporting company.
Item 8. Financial Statements.
All financial information
required by this Item is attached hereto at the end of this report beginning on page F-1 and is hereby incorporated by reference.
Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
Our management, with the participation
of our CEO and our Acting CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and
Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our CEO and our Acting
CFO concluded that our disclosure controls and procedures as of the end of the period covered by this report, in light of the material
weaknesses described below, were not effective to ensure that information required to be disclosed is made known to management and
others, as appropriate, to allow timely decision regarding required disclosure and that the information required to be disclosed by us
in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified
in the Commission’s rules and forms and (ii) accumulated and communicated to our management, including our CEO and Acting CFO, or
persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including
our CEO and Acting CFO, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or
fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives
of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and
the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. To address the
material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial statements
included in this Annual Report have been prepared in accordance with generally accepted accounting principles. Accordingly, management
believes that the financial statements included in this report fairly present in all material respects our financial condition, results
of operations and cash flows for the periods presented.
Management’s Annual Report on Internal
Control over Financial Reporting.
Our management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities
Exchange Act, as amended. Our internal control over financial reporting is a process designed to provide reasonable, but not absolute,
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls
may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. We have
identified the following material weakness:
| 1. | As of June 30, 2024, due to
the inherent issue of segregation of duties in a small company, we have relied heavily on entity or management review controls and engaged
an outside financial consultant to lessen the issue of segregation of duties over accounting, financial close procedures and controls
over financial statement disclosure. Accordingly, management has determined that this control deficiency constitutes a material weakness. |
In making its assessment of
internal control over financial reporting, management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) in Internal Control—Integrated Framework (2013). Management has concluded that, at June 30, 2024, the Company’s
internal control over financial reporting were not effective based on those criteria.
The weaknesses and the related
risks are not uncommon in a company of our size because of the limitations in the size and number of staff. To address these material
weaknesses, we intend to undertake remediation measures to address the material weaknesses described in this Report, including implementing
procedures pursuant to which we can ensure segregation of duties and hire additional resources to ensure appropriate review and oversight.
This annual report does not
include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting.
Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of
the SEC that permit the Company to provide only management’s report in this annual report.
Changes in Internal Controls
There has been no change in
our internal control over financial reporting that occurred during the quarter ended June 30, 2024 that has materially affected or is
reasonably likely to materially affect our internal control over financial reporting.
Item 9B. Other Information.
During the quarter ended June
30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections.
Not applicable.
PART III
Item 10. Directors, Executive Officers and
Corporate Governance.
The following table sets forth
information about our executive officers and directors:
Name |
|
Age |
|
Position |
Timothy Young |
|
59 |
|
President, CEO, Acting CFO and Chairman of the Board of Directors |
Woosuk Kim |
|
59 |
|
Chief Operating Officer and Director |
Timothy Young – President, CEO, Acting
CFO and Chairman of the Board of Directors
Tim Young is an accomplished
executive with over fifteen years of management experience in media and Internet technology companies. Mr. Young was appointed President,
CEO and Chairman of the Company in August 2009. Mr. Young was appointed Acting CFO in 2010.
Through his outreach to the
public and to leaders in the renewable energy field, Mr. Young has bolstered the company’s visibility as a key player in the developing
green hydrogen market and rallied a strong investor base. Mr. Young’s proven fundraising ability, along with his leadership and
direction of SunHydrogen’s long-term and short-term goals and strategies, has enabled the company to engage international industrial
partners, attract top industry scientists, and most importantly continue to hit milestones toward commercializing its nanoparticle-based
green hydrogen technology.
Prior to founding SunHydrogen,
Mr. Young demonstrated a track record of success in management and leadership positions bringing new products to the market in the digital,
cable and broadcast media industries. Mr. Young was the President of Rovion, a digital advertising
company, where he increased revenues through a channel sales strategy that included companies such as Clear Channel, Disney, CBS, and
Fox Television and bolstered the company’s technical capabilities through strategic acquisitions.
Prior
to Rovion, Mr. Young enjoyed a decade-long career at Time Warner Inc. where he served as Vice President and Regional Vice President of
various divisions including America Online and Time Warner Cable. During his tenure, Mr. Young built some of the highest performing sales
organizations at Time Warner with responsibilities ranging from product development and marketing to staff training and leadership development.
He led the California and Hawaii sales teams which accounted for over $200 million in revenues with 250 sales and marketing personnel.
Mr. Young’s track record
of success and over fifteen years of management and leadership experience bringing new products to the market qualifies him to be a board
member of the Company.
Woosuk Kim – Chief Operating Officer
and Director
Woosuk Kim has served as our
chief operating officer and director since April 1, 2021. From May 2011 to December 2019, Mr. Kim was senior vice president, head of M&A
group at SK Innovation in Seoul, South Korea, responsible for expanding core businesses and developing new business opportunities in the
renewable energy sector through cross border acquisitions and joint venture transactions. From August 2009 to May 2011 Mr. Kim was vice
president, corporate development at SK Telekom. From August 2006 to March 2008, Mr. Kim was chief financial officer at Axon Financial
Services in New York. From July 1998 to August 2006, Mr. Kim was executive director at Morgan Stanley in New York, responsible for developing
and operating multi-billion dollar asset-backed securities funding platforms, investor marketing, and the corporate treasury function
for Discover Card. He received an MBA from Cornell University and a BA from the University of Chicago.
Mr. Kim’s financial
industry knowledge and experience qualify him to serve on our board of directors.
Directors are elected at our
annual meeting of shareholders and serve for one year until the next annual meeting of shareholders or until their successors are elected
and qualified.
Family Relationships
There are no family relationships
among our executive officers and directors.
Board Leadership Structure and Role in Risk
Oversight
Although we have not adopted
a formal policy on whether the Chairman and Chief Executive Officer positions should be separate or combined, we have traditionally determined
that it is in the best interests of the Company and its shareholders to combine these roles. Currently, our Chief Executive Officer also
serves as Chairman of the Board. Due to the small size and early stage of the Company, we believe it is currently most effective to have
the Chairman and Chief Executive Officer positions combined.
Involvement in Certain Legal Proceedings
During the past ten years,
none of our directors, executive officers, promoters, control persons, or nominees has been:
| ● | the
subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time; |
| ● | convicted
in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); |
| ● | subject
to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or any Federal
or State authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business,
securities or banking activities; |
| ● | found
by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated
a federal or state securities or commodities law. |
| ● | the
subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed,
suspended or vacated, relating to an alleged violation of (a) any Federal or State securities or commodities law or regulation; (b) any
law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction,
order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
order; or (c) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or |
| ● | the
subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of
the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary
authority over its members or persons associated with a member. |
Committees of the Board
Due to the small size of the
Company and its Board of Directors, we currently have no audit committee, compensation committee or nominations and governance committee
of our board of directors. We do not have an audit committee financial expert.
Code of Ethics
We have adopted a Code of
Ethics that applies to all of our directors, officers and employees. A copy of the Code of Ethics can be obtained without charge upon
request to Timothy Young, CEO and President, BioVentures Center, 2500 Crosspark Road, Coralville, IA 52241 and is also being incorporated
by reference herein. Any waiver of the provisions of the Code of Ethics for executive officers and directors may be made only by the Board
of Directors. Any such waivers will be promptly disclosed to our shareholders.
Changes in Nominating Procedures
None.
Insider Trading Policies
We have not adopted an
insider trading policy governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees.
Item 11. Executive Compensation
The table below sets forth
the compensation earned by our named executive officers during the last two fiscal years.
Name & Principal Position | |
Year | | |
Salary
($) | | |
Bonus
($) | | |
Stock
Awards ($) | | |
Option
Awards
($) | | |
Non Equity
Incentive Plan
Compensation
($) | | |
Non-Qualified
Deferred
Compensation
Earnings ($) | | |
All Other
Compensation
($) | | |
Total ($) | |
Timothy Young, | |
| 2024 | | |
$ | 367,616 | | |
$ | 354,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 721,616 | |
CEO and Acting CFO | |
| 2023 | | |
$ | 354,000 | | |
$ | 354,000 | | |
$ | 2,700,000 | (1) | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 3,408,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Woosuk Kim, | |
| 2024 | | |
$ | 285,577 | | |
$ | 206,250 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 491,827 | |
COO | |
| 2023 | | |
$ | 275,000 | | |
$ | 206,250 | | |
| 1,350,000 | (1) | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 1,831,250 | |
(1) |
Mr. Young and Mr. Kim were awarded restricted stock on November 8, 2022. |
Outstanding Equity Awards at Fiscal Year-End
The following table discloses
information regarding outstanding equity awards granted or accrued as of June 30, 2024, for our named executive officers.
Outstanding Equity Awards |
| |
Option Awards | | |
Stock Awards | |
Name | |
Number of Securities Underlying Unexercised (#) Exercisable | | |
Number of Securities Underlying Unexercised Options (#) Unexercisable | | |
Option Exercise Price ($) | | |
Option Expiration Date | | |
Number of Shares or Units of Stock that have not Vested (#) | | |
Market Value of Shares or Units of Stock that have not Vested ($) | |
Timothy Young | |
| 125,812,947 | | |
| - | | |
| .0099 | | |
| 1/23/2026 | | |
| - | | |
| - | |
Woosuk Kim | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Director Compensation
The following table sets forth
compensation information regarding the Company’s non-employee directors in fiscal 2024:
Name | |
Fees earned or paid in cash | | |
Stock Award ($) | | |
Option Awards ($) | | |
Non-equity incentive plan compensation | | |
Nonqualified deferred compensation earnings | | |
Non-Equity Incentive Plan Compensation ($) | | |
Non-Qualified Deferred Compensation Earnings ($) | | |
All Other Compensation ($) | | |
Total ($) | |
Mark R. Richardson | |
$ | 42,000 | | |
$ | - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 42,000 | |
Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.
The following table sets forth
certain information, as of September 23, 2024, concerning the number of shares of our common stock owned by: (i) each of our directors;
(ii) each of our named executive officers; and (iii) each person or group known by us to beneficially own more than 5% of our outstanding
shares of common stock.
We believe that all persons
named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them.
A person is deemed to be the
beneficial owner of securities that can be acquired by him within 60 days of September 23, 2024, upon the exercise or conversion of options,
warrants or convertible securities. Each beneficial owner’s percentage ownership is determined by assuming that options, warrants
or convertible securities that are held by him, but not those held by any other person, and which are exercisable within 60 days of September
26, 2024 or have been exercised and converted.
| |
Shares Beneficially Held | | |
Percentage of Common Stock(1) | |
Timothy A. Young(2) | |
| 196,462,947 | | |
| 3.7 | % |
Mark R. Richardson(3) | |
| 6,081,552 | | |
| * | |
Woosuk Kim | |
| 24,950,000 | | |
| * | |
All officers and directors as a group (3 persons) | |
| 227,494,499 | | |
| 4.3 | % |
* | Less
than 1% |
(1) |
Based upon 5,156,352,593 shares issued and outstanding as of September 26,
2024. |
(2) |
Includes 125,812,947 shares underlying options. |
(3) |
Includes 3,081,552 shares
underlying options. Mr. Richardson resigned effective September 30, 2024. |
The address for each of the officers and directors is c/o SunHydrogen, Inc. BioVentures Center, 2500 Crosspark Road, Coralville, IA 52241
Securities authorized for issuance under equity
compensation plans
On January 23, 2019, our Board
adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”). The purpose of the 2019 Plan is to promote the success
of the Company and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain
and reward selected employees and other eligible persons. The maximum number of shares of the Company’s common stock that can be
issued under the 2019 Plan is 300,000,000. The 2019 Plan has been approved by stockholders.
On
January 27, 2022, our Board adopted the Company’s 2022 Equity Incentive Plan (the “2022 Plan”). The stated purpose of
the 2022 Plan is to attract and retain the types of employees, consultants, and directors who will contribute to the Company’s long-range
success. The maximum number of shares of the Company’s common stock that can be issued under the 2022 Plan is initially 400,000,000.
The number of shares automatically increases on the first day of the Company’s fiscal year beginning in 2023 so that
the total number of shares issuable will at all times equal fifteen percent (15%) of the Company’s fully diluted capitalization
on the first day of the Company’s fiscal year, unless the Board adopts a resolution providing that the number of shares issuable
under the 2022 Plan shall not be so increased.
The following table sets forth information
about our equity compensation plans as of June 30, 2024.
Plan Category | |
Number of
securities to
be issued
upon
exercise of
outstanding
options,
warrants
and rights | | |
Weighted-
average
exercise
prices of
outstanding
options,
warrants
and rights | | |
Number of
securities
remaining
available for
future
issuance
under the
equity
compensation
plans
(excluding
securities
reflected in
column (a)) | |
| |
(a) | | |
(b) | | |
| |
2019 Equity compensation plan approved by security holders | |
| 285,270,561 | | |
$ | 0.0099 – 0.016 | | |
| 14,729,439 | |
2022 Equity compensation plan approved by security holders | |
| 173,600,000 | | |
$ | 0.012 | | |
| 549,594,742 | |
Total | |
| 458,870,561 | | |
| | | |
| 564,324,181 | |
Item 13. Certain Relationships and Related
Transactions, and Director Independence.
Certain Relationships and Related Transactions
As of June 30, 2024, the Company
owed $45,829 to Timothy Young for a loan payable for the payment of operating expenses in prior periods.
Director Independence
The Board has determined that
Mr. Richardson was an independent director within the meaning of NASDAQ Rule 5605(a)(2). He resigned effective September 30, 2024.
Item 14. Principal Accountant Fees and Services.
Audit Fees
The aggregate fees billable
to us by our principal accounting firm during the years ended June 30, 2024 and 2023 for the audit of our annual financial statements
and review of financial statements included in our Form 10-Qs or services that are normally provided by the accountant in connection with
statutory and regulatory filings or engagements for those fiscal years, were approximately $66,725 and $32,000, respectively.
Audit-Related Fees
We incurred fees of $0 and
$0 for the years ended June 30, 2024 and 2023, respectively, to our principal accountant for assurance and related services that are reasonably
related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees” above.
Tax Fees
We did not incur fees for
services rendered to us for tax compliance, tax advice, or tax planning by our principal accountant for the fiscal years ended June 30,
2024 and 2023.
All Other Fees
Our current policy is to not
engage M&K CPAS, PLLC to provide, among other things, bookkeeping services, appraisal or valuation services, or international audit
services. The policy provides that we engage M&K CPAS, PLLC to provide audit, and other assurance services, such as review of SEC
reports or filings.
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(1) Financial statements.
The SunHydrogen, Inc. financial statements are
included in Item 8. Financial Statements and Supplementary Data.
(2) Financial statement schedules: None.
(3) Exhibits
Exhibit |
|
Description |
|
|
|
3.1 |
|
Articles of Incorporation of filed with the Nevada Secretary of State on February 18, 2009 (incorporated by reference to S-1 filed on February 5, 2010). |
|
|
|
3.2 |
|
Articles of Amendment of Articles of Incorporation filed with the Nevada Secretary of State on September 11, 2009 (incorporated by reference to S-1 filed February 5, 2010). |
|
|
|
3.3 |
|
Articles of Amendment of Articles of Incorporation of filed with the Nevada Secretary of State on November 21, 2013 (incorporated by reference 8-K filed on November 21, 2013). |
|
|
|
3.4 |
|
Articles of Amendment of Articles of Incorporation filed with the Nevada Secretary of State on September 13, 2018. (incorporated by reference to 10-K filed on September 25, 2018). |
|
|
|
3.5 |
|
Certificate of Designation of Series A Preferred Stock (incorporated by reference to the Company’s Form 8-K filed February 2, 2022) |
|
|
|
3.6 |
|
Certificate of Designation of Series B Preferred Stock (incorporated by reference to the Company’s Form 8-K filed November 26, 2019) |
|
|
|
3.7 |
|
Certificate of Designation of Series C Preferred Stock (incorporated by reference to the Company’s Form 8-K filed December 17, 2021) |
|
|
|
3.8 |
|
Certificate of Amendment to Articles of Incorporation (incorporated by reference to 8-K filed January 3, 2020) |
|
|
|
3.9 |
|
Articles of Merger (incorporated by reference to 8-K filed June 15, 2020) |
|
|
|
3.10 |
|
Certificate of Amendment to Articles of Incorporation (incorporated by reference to 10-Q filed May 16, 2022) |
|
|
|
3.11 |
|
Amended and Restated Bylaws (incorporated by reference to 8-K filed February 2, 2022) |
|
|
|
4.1 |
|
Description of Registrant’s Securities (incorporated by reference to 10-K filed October 8, 2021) |
|
|
|
10.1 |
|
2019 Equity Incentive Plan (incorporated by reference to Form S-8 on December 19, 2018) |
10.2 |
|
Form of Placement Agent Warrant (incorporated by reference to 8-K filed December 3, 2020) |
|
|
|
10.3 |
|
Form of Warrant (incorporated by reference to 8-K filed February 26, 2021) |
|
|
|
10.4 |
|
Form of Placement Agent Warrant (incorporated by reference to 8-K filed February 26, 2021) |
|
|
|
10.5 |
|
Employment Agreement between the Company and Timothy Young (incorporated by reference to 8-K filed March 1, 2021) *** |
|
|
|
10.6 |
|
Employment Agreement between the Company and Woosuk Kim (incorporated by reference to 8-K filed April 7, 2021) *** |
|
|
|
10.7 |
|
Contract, dated October 1, 2022, between the Company and The University of Iowa, Iowa City (incorporated by reference to Form 10-K filed October 7, 2022) |
|
|
|
10.8 |
|
Research Agreement Amendment No. 1 between the Company and Regents of the University of Michigan (incorporated by reference to Form 10-K filed October 7, 2022) |
|
|
|
10.9 |
|
Research Agreement Amendment No. 1 between the Company and Regents of the University of Michigan (incorporated by reference to Form 10-K filed October 7, 2022) |
|
|
|
10.10 |
|
SunHydrogen, Inc. 2022 Stock Incentive Plan (incorporated by reference to Form 10-K filed October 7, 2022) |
|
|
|
10.11 |
|
Purchase Agreement (incorporated by reference to 8-K filed June 3, 2024) |
|
|
|
10.12**** |
|
Joint Development Agreement dated July 22, 2024 (incorporated by reference to 8-K filed July 24, 2024) |
|
|
|
10.13**** |
|
Collaboration Agreement (incorporated by reference to 8-K filed July 23, 2024) |
|
|
|
14.1 |
|
Code of Ethics (incorporated by reference to 10-K filed on September 28, 2012). |
|
|
|
23.1* |
|
Consent of M&K CPAS, LLC |
|
|
|
31.1* |
|
Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302 |
|
|
|
32.1** |
|
Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350 |
|
|
|
101 |
|
Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. |
|
|
|
104 |
|
Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set. |
*** | Indicates management contract or compensatory plan or arrangement. |
**** | Portions
of this agreement have been omitted. |
Item 16. Form 10-K Summary.
None.
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
SUNHYDROGEN, INC. |
|
|
|
Date: September 30, 2024 |
By: |
/s/ Timothy Young |
|
|
Timothy Young
Chief Executive Officer,
Acting Chief Financial Officer, and Chairman
(principal executive, financial and
accounting officer) |
Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Timothy Young |
|
Chief Executive Officer, President |
|
September 30, 2024 |
Timothy Young |
|
(Principal Executive Officer) Acting Chief Financial Officer
(Principal Financial and Accounting Officer), and Chairman |
|
|
|
|
|
|
|
/s/ Woosuk Kim |
|
Director |
|
September 30, 2024 |
Woosuk Kim |
|
|
|
|
SUN HYDROGEN, INC.
TABLE OF CONTENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Board of Directors and
Stockholders of Sun Hydrogen, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance
sheets of Sun Hydrogen, Inc. (the Company) as of June 30, 2024 and 2023, and the related statements of operations,
shareholders’ equity (deficit), and cash flows for each of the years in the two-year period ended June 30, 2024, and the
related notes (collectively referred to as the “ financial statements”). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its
operations and its cash flows for each of the years in the two-year period ended June 30, 2024 in conformity with accounting
principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is
a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the
audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions
on the critical audit matter or on the accounts or disclosures to which it relates.
Investments
As discussed in Note 8 to the financial statements,
the Company has investments in a related party, consisting of both equity securities and bonds. The investment is subject to fair value
measurement, with the equity securities marked to market in accordance with the applicable financial reporting standards. Additionally,
during the fiscal year, the Company converted the bonds held in the related party into equity securities of the same entity.
| ● | The equity securities of the related party are marked
to market and the determination of fair value involves judgment and reliance on valuation techniques. |
| ● | The conversion of bonds to equity in the related party
involved complex accounting considerations. There was also complexity in assessing the appropriate accounting for the conversion and
subsequent measurement of the equity securities received. |
| ● | The investment in the related party requires additional
disclosure and evaluation of the relationship between the Company and the related party entity. We focused on the adequacy of the related
party disclosures, including the identification of the related party, the nature of the relationship, and any transactions that occurred
between the entities. |
Addressing these matters required the application
of heightened professional skepticism in evaluating management’s assumptions regarding the valuation of both the equity securities and
the conversion of the bonds.
/s/ M&K CPAS, PLLC
We have served as the Company’s auditor since 2020
The Woodlands, TX
September 30, 2024
SUNHYDROGEN, INC.
BALANCE SHEETS
| |
June 30, 2024 | | |
June 30, 2023 | |
| |
| | |
| |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | |
| |
Cash and cash equivalents | |
$ | 39,044,795 | | |
$ | 37,185,989 | |
Marketable securities | |
| - | | |
| 3,188,040 | |
Equity securities, related party | |
| 4,101,402 | | |
| 7,655,601 | |
| |
| | | |
| | |
TOTAL CURRENT ASSETS | |
| 43,146,197 | | |
| 48,029,630 | |
| |
| | | |
| | |
OTHER ASSETS | |
| | | |
| | |
| |
| | | |
| | |
INVESTMENT | |
| | | |
| | |
Convertible notes receivable, related party | |
| - | | |
| 3,000,000 | |
| |
| | | |
| | |
TOTAL INVESTMENTS | |
| - | | |
| 3,000,000 | |
| |
| | | |
| | |
PROPERTY & EQUIPMENT | |
| | | |
| | |
Machinery and equipment | |
| 36,830 | | |
| 33,814 | |
Computers and peripherals | |
| 11,529 | | |
| 11,529 | |
Vehicle | |
| 135,260 | | |
| 155,000 | |
| |
| 183,619 | | |
| 200,343 | |
Less: accumulated depreciation | |
| (20,549 | ) | |
| (83,468 | ) |
| |
| | | |
| | |
NET PROPERTY AND EQUIPMENT | |
| 163,070 | | |
| 116,875 | |
| |
| | | |
| | |
INTANGIBLE ASSETS | |
| | | |
| | |
Domain, net of amortization of $5,315 and $5,286, respectively | |
| - | | |
| 29 | |
Trademark, net of amortization of $827 and $714, respectively | |
| 315 | | |
| 428 | |
Patents, net of amortization of $42,909 and $36,344, respectively | |
| 58,234 | | |
| 64,799 | |
| |
| | | |
| | |
TOTAL INTANGIBLE ASSETS | |
| 58,549 | | |
| 65,256 | |
| |
| | | |
| | |
TOTAL OTHER ASSETS | |
| 221,619 | | |
| 3,182,131 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 43,367,816 | | |
$ | 51,211,761 | |
| |
| | | |
| | |
LIABILITIES, PREFERRED STOCK SUBJECT TO REDEMPTION AND SHAREHOLDERS’ DEFICIT | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable and other payables | |
$ | 573,127 | | |
$ | 232,893 | |
Accrued expenses | |
| 140,558 | | |
| 628 | |
Loan payable, related party | |
| 45,829 | | |
| 106,728 | |
| |
| | | |
| | |
TOTAL CURRENT LIABILITIES | |
| 759,514 | | |
| 340,249 | |
| |
| | | |
| | |
LONG TERM LIABILITIES | |
| | | |
| | |
Loan payable, related party | |
| - | | |
| 36,731 | |
| |
| | | |
| | |
TOTAL LONG TERM LIABILITIES | |
| - | | |
| 36,731 | |
| |
| | | |
| | |
TOTAL LIABILITIES | |
| 759,514 | | |
| 376,980 | |
| |
| | | |
| | |
COMMIMENTS AND CONTINGENCIES (SEE NOTE 9) | |
| | | |
| | |
| |
| | | |
| | |
| |
| | | |
| | |
Series C 10% Preferred Stock, 8,851 and 10,951 shares issued and outstanding, redeemable value of $885,100 and $1,095,100, respectively | |
| 885,100 | | |
| 1,095,100 | |
| |
| | | |
| | |
SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Preferred Stock, $0.001 par value; 5,000,000 authorized preferred shares | |
| - | | |
| - | |
Common Stock, $0.001 par value; 10,000,000,000 authorized common shares 5,087,245,974 and 4,821,298,283 shares issued and outstanding, respectively | |
| 5,087,246 | | |
| 4,821,298 | |
Additional Paid in Capital | |
| 128,488,199 | | |
| 126,889,423 | |
Accumulated deficit | |
| (91,852,243 | ) | |
| (81,971,040 | ) |
| |
| | | |
| | |
TOTAL SHAREHOLDERS’ EQUITY | |
| 41,723,202 | | |
| 49,739,681 | |
| |
| | | |
| | |
TOTAL LIABILITIES, PREFERRED STOCK SUBJECT TO REDEEMPTION AND SHAREHOLDERS’ EQUITY | |
$ | 43,367,816 | | |
$ | 51,211,761 | |
The accompanying notes are an integral part of these financial statements
SUNHYDROGEN, INC.
STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023
| |
YEARS ENDED | |
| |
June 30,
2024 | | |
June 30,
2023 | |
| |
| | |
| |
REVENUE | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | |
Selling and Marketing | |
| 53,831 | | |
| 131,745 | |
General and administrative expenses | |
| 2,336,952 | | |
| 5,651,728 | |
Research and development cost | |
| 2,568,562 | | |
| 3,440,106 | |
Depreciation and amortization | |
| 41,955 | | |
| 43,568 | |
| |
| | | |
| | |
TOTAL OPERATING EXPENSES | |
| 5,001,300 | | |
| 9,267,147 | |
| |
| | | |
| | |
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) | |
| (5,001,300 | ) | |
| (9,267,147 | ) |
| |
| | | |
| | |
OTHER INCOME/(EXPENSES) | |
| | | |
| | |
Investment income | |
| 2,013,974 | | |
| 1,149,859 | |
Gain on sale of vehicle | |
| 55,166 | | |
| - | |
Dividend expense | |
| (112,940 | ) | |
| (27,000 | ) |
Unrealized Gain(loss) on equity securities, related party | |
| (6,693,501 | ) | |
| 655,601 | |
Realized gain (loss) | |
| (173,124 | ) | |
| (3,735 | ) |
Realized gain(loss) on redemption of marketable securities | |
| 35,080 | | |
| - | |
Gain (Loss) on settlement of derivative liability | |
| - | | |
| (664,627 | ) |
Gain (Loss) on change in derivative liability | |
| - | | |
| 9,204,345 | |
Interest expense | |
| (4,558 | ) | |
| (72,317 | ) |
| |
| | | |
| | |
TOTAL OTHER INCOME (EXPENSES) | |
| (4,879,903 | ) | |
| 10,242,126 | |
| |
| | | |
| | |
NET INCOME (LOSS) | |
$ | (9,881,203 | ) | |
$ | 974,979 | |
| |
| | | |
| | |
BASIC EARNINGS (LOSS) PER SHARE | |
$ | (0.00 | ) | |
$ | 0.00 | |
| |
| | | |
| | |
DILUTED EARINGINS (LOSS) PER SHARE | |
$ | (0.00 | ) | |
$ | 0.00 | |
| |
| | | |
| | |
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING | |
| | | |
| | |
BASIC | |
| 5,028,399,413 | | |
| 4,492,448,483 | |
| |
| | | |
| | |
DILUTED | |
| 5,028,399,413 | | |
| 4,787,349,172 | |
The accompanying notes are an integral part of these audited financial statements
SUNHYDROGEN, INC.
STATEMENTS OF SHAREHOLDERS’ EQUITY/(DEFICIT)
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023
| |
YEAR ENDED JUNE 30, 2024 | |
| |
| | |
| | |
| | |
| | |
| | |
Additional | | |
| | |
| |
| |
Preferred stock | | |
| | |
Common stock | | |
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Mezzanine | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance at June 30, 2023 | |
| - | | |
$ | - | | |
$ | 1,095,100 | | |
| 4,821,298,283 | | |
$ | 4,821,298 | | |
$ | 126,889,423 | | |
$ | (81,971,040 | ) | |
$ | 49,739,681 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock upon partial conversion of purchase agreement for cash | |
| - | | |
| - | | |
| - | | |
| 86,395,059 | | |
| 86,395 | | |
| 792,530 | | |
| - | | |
| 878,925 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock upon conversion of Series C Preferred stock | |
| - | | |
| - | | |
| (210,000 | ) | |
| 221,052,632 | | |
| 221,053 | | |
| (11,053 | ) | |
| - | | |
| 210,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cancellation of restricted stock awards | |
| - | | |
| - | | |
| - | | |
| (41,500,000 | ) | |
| (41,500 | ) | |
| (576,500 | ) | |
| - | | |
| (618,000 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Contributed capital-gain on conversion of bond | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 85,815 | | |
| - | | |
| 85,815 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,307,984 | | |
| - | | |
| 1,307,984 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (9,881,203 | ) | |
| (9,881,203 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at June 30, 2024 | |
| - | | |
$ | - | | |
$ | 885,100 | | |
| 5,087,245,974 | | |
$ | 5,087,246 | | |
$ | 128,488,199 | | |
$ | (91,852,243 | ) | |
$ | 41,723,202 | |
| |
YEAR ENDED JUNE 30, 2023 | |
| |
| | |
| | |
| | |
| | |
| | |
Additional | | |
| | |
| |
| |
Preferred stock | | |
| | |
Common stock | | |
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Mezzanine | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance at June 30, 2022 | |
| - | | |
| - | | |
$ | 270,000 | | |
| 4,271,749,146 | | |
$ | 4,271,749 | | |
$ | 103,311,733 | | |
$ | (82,946,019 | ) | |
$ | 24,637,463 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock upon partial conversion of purchase agreement for cash | |
| - | | |
| - | | |
| - | | |
| 141,316,755 | | |
| 141,316 | | |
| 2,592,178 | | |
| - | | |
| 2,733,494 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock for conversion of debt and accrued interest | |
| - | | |
| - | | |
| - | | |
| 274,198,530 | | |
| 274,199 | | |
| (13,710 | ) | |
| - | | |
| 260,489 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock for the conversion of stock options | |
| - | | |
| - | | |
| - | | |
| 1,933,852 | | |
| 1,934 | | |
| 30,941 | | |
| - | | |
| 32,875 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock for conversion of restricted
stock awards | |
| - | | |
| - | | |
| - | | |
| 44,500,000 | | |
| 44,500 | | |
| 1,068,000 | | |
| - | | |
| 1,112,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of stock for conversion of restricted stock awards | |
| - | | |
| - | | |
| - | | |
| 87,600,000 | | |
| 87,600 | | |
| (87,600 | ) | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of Series C preferred stock in exchange for convertible notes at fair value | |
| - | | |
| - | | |
| 825,100 | | |
| - | | |
| - | | |
| 17,475,309 | | |
| - | | |
| 17,475,309 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock compensation for conversion of restricted stock awards | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 2,365,200 | | |
| - | | |
| 2,365,200 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 147,372 | | |
| - | | |
| 147,372 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 974,979 | | |
| 974,979 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at June 30, 2023 | |
| - | | |
$ | - | | |
$ | 1,095,100 | | |
$ | 4,821,298,283 | | |
$ | 4,821,298 | | |
$ | 126,889,423 | | |
$ | (81,971,040 | ) | |
$ | 49,739,681 | |
The accompanying notes are an integral part of these audited financial
statements
SUNHYDROGEN, INC.
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2024 AND 2023
| |
Years Ended | |
| |
June 30,
2024 | | |
June 30,
2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net Income (Loss) | |
| (9,881,203 | ) | |
| 974,979 | |
Adjustment to reconcile net income (loss) to net cash | |
| | | |
| | |
(used in) provided by operating activities | |
| | | |
| | |
Depreciation & amortization expense | |
| 41,955 | | |
| 43,568 | |
Conversion of stock options for services | |
| - | | |
| 32,875 | |
Stock based compensation expense for services | |
| 1,307,984 | | |
| 22,372 | |
Cancellation of restricted stock awards | |
| (618,000 | ) | |
| - | |
Realized loss on sale of investment | |
| 188,040 | | |
| - | |
Gain on exchange of vehicle | |
| (55,166 | ) | |
| - | |
Net stock compensation expense for conversion of restricted stock awards | |
| - | | |
| 3,602,700 | |
Loss on settlement of debt and derivative | |
| - | | |
| 664,669 | |
Net (Gain) Loss on change in derivative liability | |
| - | | |
| (9,204,387 | ) |
Unrealized (gain)/loss on change in fair value of investment, related party | |
| 6,693,501 | | |
| (655,601 | ) |
Change in assets and liabilities : | |
| | | |
| | |
Prepaid expense | |
| - | | |
| 2,526 | |
Other receivable | |
| - | | |
| 14,868 | |
Accounts payable | |
| 340,233 | | |
| 175,504 | |
Accrued expenses | |
| 139,930 | | |
| (2,442 | ) |
Accrued interest on convertible notes | |
| - | | |
| 66,284 | |
| |
| | | |
| | |
NET CASH USED IN OPERATING ACTIVITIES | |
| (1,842,726 | ) | |
| (4,262,085 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES | |
| | | |
| | |
Marketable securities purchased | |
| - | | |
| (81,971,636 | ) |
Marketable securities redeemed | |
| - | | |
| 103,106,836 | |
Purchase of certificate of deposit | |
| (5,000,000 | ) | |
| - | |
Redemption of certificate of deposit | |
| 5,000,000 | | |
| - | |
Convertible note receivable interest income, related party | |
| (53,487 | ) | |
| - | |
Purchase of investment, related party | |
| - | | |
| (7,000,000 | ) |
Purchase of long term convertible note, related party | |
| - | | |
| (3,000,000 | ) |
Redemption of short term investments in corporate securities | |
| 3,000,000 | | |
| - | |
Purchase of research and development equipment | |
| (3,016 | ) | |
| - | |
Purchase of vehicle | |
| (23,260 | ) | |
| - | |
Purchase of tangible assets | |
| - | | |
| (33,814 | ) |
| |
| | | |
| | |
NET PROVIDED BY INVESTING ACTIVITIES: | |
| 2,920,237 | | |
| 11,101,386 | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Repayment of related party note payable | |
| (97,630 | ) | |
| (68,291 | ) |
Net proceeds from purchase agreements | |
| 878,925 | | |
| 2,733,494 | |
| |
| | | |
| | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | |
| 781,295 | | |
| 2,665,203 | |
| |
| | | |
| | |
NET INCREASE IN CASH | |
| 1,858,806 | | |
| 9,504,504 | |
| |
| | | |
| | |
CASH, BEGINNING OF PERIOD | |
| 37,185,989 | | |
| 27,681,485 | |
| |
| | | |
| | |
CASH, END OF PERIOD | |
| 39,044,795 | | |
| 37,185,989 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |
| | | |
| | |
Interest paid | |
$ | 4,558 | | |
$ | 6,033 | |
Taxes paid | |
| | | |
$ | - | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS | |
| | | |
| | |
Fair value of common stock upon conversion of convertible notes, and accrued interest | |
$ | - | | |
$ | 260,489 | |
Fair value of preferred stock in exchange for convertible note | |
$ | - | | |
$ | 17,475,309 | |
Reclassification of related party accrued salary to loan payable | |
$ | - | | |
$ | 211,750 | |
Conversion of Series C Preferred shares to common stock | |
$ | 210,000 | | |
$ | - | |
Reclassification of related party accrued salary to loan payable | |
$ | - | | |
$ | 16,810,682 | |
Exchange of convertible note receivable, related party | |
$ | 3,000,000 | | |
$ | - | |
Contributed capital-gain on exchange of convertible note receivable, related party | |
$ | 85,815 | | |
$ | - | |
The accompanying notes are an integral part of these audited financial
statements
SUNHYDROGEN, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2024 AND 2023
1. |
ORGANIZATION AND LINE OF BUSINESS |
Organization
SunHydrogen, Inc. (the “Company”)
was incorporated in the state of Nevada on February 18, 2009. The Company, based in Coralville, IA began operations on February 19, 2009.
Line of Business
The company is currently developing a novel solar-powered
nanoparticle system that mimics photosynthesis to separate hydrogen from water. We intend for technology of this system to be used for
the production of renewable hydrogen to produce renewable electricity and hydrogen for fuel cells and other applications where hydrogen
is used.
SunHydrogen is developing
an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source
of water. Just like a solar panel is comprised of multiple cells that generate electricity, our hydrogen panel encases multiple
hydrogen generators immersed in water. Each hydrogen generator contains billions of electroplated nanoparticles, autonomously splitting
water into hydrogen and oxygen. Our technology has the potential to be one of – if not the most – economical green hydrogen
solutions: Unlike traditional water electrolysis for hydrogen, our process requires no external power other than sunlight and uses efficient
and low-cost materials.
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
This summary of significant accounting policies
of SunHydrogen, Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes
are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies
conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation
of the financial statements.
Cash and Cash Equivalent
The Company considers all highly liquid investments
with an original maturity of three months or less to be cash equivalents.
The following table provides detail of our cash
and cash equivalents.
| |
June 30,
2024 | | |
June 30,
2023 | |
Cash | |
$ | 29,365,997 | | |
$ | 13,928,552 | |
U.S. Treasury bills | |
| 9,678,798 | | |
| 22,157,437 | |
U.S. Treasury obligations | |
| - | | |
| 1,100,000 | |
Total cash and cash equivalents | |
$ | 39,044,795 | | |
$ | 37,185,989 | |
The U.S. Treasury bills and the U.S. Treasury
obligations have a credit quality indicator of AA/A.
Concentration risk
Cash includes amounts deposited in financial institutions
in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances
in certain bank accounts in excess of the FDIC limits. As of June 30, 2024, the cash balance in excess of the FDIC limits was $37,125,346.
The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Marketable Securities
Corporate bonds and U.S. Treasuries are considered
current, based on their liquidity. The Company considers corporate bonds (“bonds”) as investments due to their ratings. The
bonds are rated based on their default probability, health of the corporation’s debt structure, as well as the overall health of
the economy. The bonds fall into the category as investments if they have a rating of AAA and BBB. We consider our investments held to
maturity and we believe there are no other than temporary declines in fair value. Our investments are recorded at historical cost.
Use of Estimates
In accordance with accounting
principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates
and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation
expense, fair value of financial instruments, and other factors. Management believes it has exercised reasonable judgment in deriving
these estimates. Consequently, a change in conditions could affect these estimates.
Property and Equipment
Property and equipment
are stated at cost and are depreciated using straight line over its estimated useful lives.
Computers and peripheral equipment | | 5 Years |
Vehicle | | 5 Years |
During the year ended
June 30, 2024, the Company traded a vehicle used for a mobile office and transportation of equipment. The Company recognized a gain of
$55,166.
The Company recognized
depreciation expense of $35,247 and $36,535 for the year ended June 30, 2024 and 2023, respectively.
Intangible Assets
The Company has patent applications to protect
the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules
traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful
lives.
| | Useful Lives | | 6/30/2024 | | | 6/30/2023 | |
| | | | | | | | |
Domain-gross | | 15 years | | $ | 5,315 | | | $ | 5,315 | |
Less accumulated amortization | | | | | (5,315 | ) | | | (5,286 | ) |
Domain-net | | | | $ | - | | | $ | 29 | |
| | | | | | | | | | |
Trademark-gross | | 10 years | | $ | 1,142 | | | $ | 1,142 | |
Less accumulated amortization | | | | | (827 | ) | | | (714 | ) |
Domain-net | | | | $ | 315 | | | $ | 428 | |
| | | | | | | | | | |
Patents-gross | | 15 years | | $ | 101,143 | | | $ | 101,143 | |
Less accumulated amortization | | | | | (42,909 | ) | | | (36,344 | ) |
Patents-net | | | | $ | 58,234 | | | $ | 64,799 | |
The Company recognized amortization expense of
$6,708 and $7,033 for the year ended June 30, 2024 and June 30, 2023, respectively.
Net Earnings (Loss) per
Share Calculations
Net earnings (Loss) per share dictates
the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing
by the weighted average number of common shares outstanding during the year ended June 30, 2024 and 2023. Diluted net earnings (loss)
per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock
options and stock-based awards (Note 6).
Year Ended June 30, 2024
The Company calculated the dilutive
impact of 266,894,499 outstanding stock options and awards, 78,095,239 common stock purchase warrants, and 8,851 Series C Preferred shares,
which are convertible into shares of common stock. Stock options and awards, common stock purchase warrants, and Series C Preferred shares
were not included in the calculation of net earnings per share because their impact on income per share is antidilutive.
Year Ended June 30, 2023
The Company calculated the dilutive
impact of 163,894,499 outstanding stock options, 86,495,239 common stock purchase warrants, 54,500,000 restricted stock units, and 10,951
Series C Preferred shares, which are convertible into shares of common stock. Stock options and awards, common stock purchase warrants,
and Series C Preferred shares were included in the calculation of net earnings per share because their impact on income per share is
dilutive, and 10,000,000 of the stock options were not included, because their impact on income per share is antidilutive.
| |
Year Ended | |
| |
June 30, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Income (Loss) to common shareholders (Numerator) | |
$ | (9,881,203 | ) | |
$ | 974,979 | |
| |
| | | |
| | |
Basic weighted average number of common shares outstanding (Denominator) | |
| 5,028,399,413 | | |
| 4,492,448,483 | |
| |
| | | |
| | |
Diluted weighted average number of common shares outstanding (Denominator) | |
| 5,028,399,413 | | |
| 4,787,349,172 | |
2022
Equity Incentive Plans
On
January 27, 2022, the Company adopted the 2022 Equity Incentive Plan, to enable the Company to attract and retain the types of employees,
consultants, and directors who will contribute to the Company’s long-range success. The maximum number of shares of common stock
that may be issued under the 2022 Plan is initially 400,000,000. The number of shares will automatically be increased on the first day
of the Company’s fiscal year beginning in 2023 so that the total number of shares issuable will at all times equal fifteen percent
(15%) of the Company’s fully diluted capitalization on the first day of the Company’s fiscal year, unless the Board adopts
a resolution providing that the number of shares issuable under the 2022 Plan shall not be so increased.
As of June 30, 2024, under the
2022 Equity Incentive Plan, there were 173,600,000 stock options and shares issued, with a reserve of 549,594,742.
2019
Equity Incentive Plan
On
December 17, 2018, the Board of Directors approved and adopted the 2019 Equity Incentive Plan (“the Plan”), with 300,000,000 shares
reserved for issuance pursuant to the Plan. The purpose of the Plan is to promote the success of the Company and to increase stockholder
value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other
eligible persons. The awards are performance-based compensation that are granted under the Plan as incentive stock options (ISO) or nonqualified
stock options. The per share exercise price for each option shall not be less than 100% of the fair market value of a share of common
stock on the date of grant of the option. The Company periodically issues stock options and warrants to employees and non-employees in
non-capital raising transactions for services and for financing cost. The Company accounts for stock option grants issued and vesting
to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value
of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is
reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation
charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance
requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge is recorded in the
period of the measurement date.
As
of June 30, 2024, under the 2019 Equity Incentive Plan, there were 285,270,561 stock options and shares issued, with a reserve
of 14,729,439.
Stock Based Compensation
The Company accounts for stock option
grants issued and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards
Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance
commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based
compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are
no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge
is recorded in the period of the measurement date.
Warrant Accounting
The Company accounts for warrants to
purchase shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation
model.
Fair Value of Financial
Instruments
Fair value of financial instruments
requires disclosure of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate
that value. As of June 30, 2024, the amounts reported for cash, accrued interest and other expenses, notes payables, convertible notes,
and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial
instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair
value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and
the lowest priority to unobservable inputs (level 3 measurements).
These tiers include:
|
● |
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. |
|
● |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. |
|
● |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
We measure certain financial instruments
at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):
June 30, 2024
| |
Total | | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Equity securities, related party | |
$ | 4,101,402 | | |
$ | - | | |
$ | 4,101,402 | | |
$ | - | |
| |
$ | 4,101,402 | | |
$ | - | | |
$ | 4,101,402 | | |
$ | - | |
June 30, 2023
| |
Total | | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Equity securities, related party | |
$ | 7,655,601 | | |
$ | - | | |
$ | 7,655,601 | | |
$ | - | |
Marketable securities | |
| 3,188,040 | | |
| - | | |
| 3,188,040 | | |
| - | |
| |
$ | 10,843,641 | | |
$ | - | | |
$ | 10,843,641 | | |
$ | - | |
The following is a reconciliation of
the derivative liability for which Level 3 inputs were used in determining the approximate fair value:
Balance as of June 30, 2022 | |
$ | 26,015,069 | |
Fair value of derivative liability removed | |
| (16,810,682 | ) |
Gain on change in derivative liability | |
| (9,204,387 | ) |
Balance as of June 30, 2023 | |
$ | - | |
As of June 30, 2024 and 2023, all convertible
notes were converted into Series C Preferred Stock, and there were no derivative liabilities to report.
Research and Development
Research and development costs are
expensed as incurred. Total research and development costs were $2,568,562 and $3,440,106 for the year ended June 30, 2024 and 2023,
respectively.
Advertising and Marketing
Advertising and marketing cost are
expensed as incurred. Total advertising and marketing costs were $53,831 and $131,745 for the year ended June 30, 2024 and 2023, respectively.
Accounting for Derivatives
The Company evaluates all of its financial
instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative
financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is
then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative
financial instruments, the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative
instruments at inception and on subsequent valuation dates.
The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the
derivative instrument could be required within 12 months of the balance sheet date.
Recently Issued Accounting Pronouncements
Management believes that no recently
issued accounting standards, which are not yet effective, would have a material impact on the accompanying audited financial statements
as of June 30, 2024, if adopted at this time.
Reclassification of Expenses
Certain amounts in the 2023 financial
statements have been reclassified to conform to the presentation used in the 2024 financial statements. There was no material effect on
the Company’s previously issued financial statements.
Series C Preferred Stock
On December 15, 2021, the Company filed
a certificate of designation of Series C Preferred Stock with the Secretary of State of Nevada, designating 17,000 shares of preferred
stock as Series C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $100 and is convertible into shares of
common stock of the Company at a conversion price equal to $0.00095. The Series C Preferred Stockholders are entitled to receive out of
any funds and assets of the Company legally available prior and in preference to any declaration or payment of any dividend on the common
stock of the Company, cumulative dividends, at an annual rate of 10% of the stated value, payable in cash or shares of common stock. In
the event the Company declares or pays a dividend on its shares of common stock (other than dividend payable in shares of common stock),
the holders of Series C Preferred Stock will also be entitled to receive payment of such dividend on an as--converted basis. The Series
C Preferred Stock confers no voting rights on holders, except with respect to matters that materially and adversely affect the voting
powers, rights or preferences of the Series C Preferred Stock or as otherwise required by applicable law.
Series C Preferred Stock (Continued)
The Company entered into securities
purchase agreements with accredited investors for an exchange of convertible debt into equity. Under the purchase agreements, the Company
and the investors exchanged convertible notes in the amount of $837,800, plus interest in the amount of $255,423, for an aggregate total
of $1,095,100 in convertible notes, for 10,951 shares of the Company’s Series C Preferred Stock.
A valuation was prepared based on a
stock price of $0.020 as of April 15, 2023 and $0.0185 as of June 19, 2023, with a volatility of 96.6%, as of April 15, 2023 and 82.9%
as of June 19, 2023 based on an estimated term of 5 years.
On December 15, 2021, the Company
entered into a securities purchase agreement with an accredited investor for an exchange of convertible debt to equity. Under the
purchase agreement, the Company and investor acknowledged there was $187,800 of principal remaining under the note issued to the
investor by the Company on February 3, 2017, plus $80,365 of accrued interest, representing a total aggregate note balance of
$268,165, and a loss on settlement of debt of $1,835. Pursuant to the purchase agreement, the Company sold 2,700 shares of the
Company’s newly designated Series C Preferred Stock to an investor, for a total purchase price of $268,165. The investor
tendered the Note to the Company for cancellation and agreed to forego all future accrued interest under the Note, as the total
purchase price for the shares.
On April 15, 2023, the Company entered
into another securities purchase agreement with an investor to exchange the remaining notes with principal of $550,000, plus accrued interest
of $126,455, representing a total aggregate note balance of $676,455, and a loss on settlement of debt of $45. Pursuant to the purchase
agreement, the Company sold 6,765 shares of the Company’s Series C Preferred Stock to the investor, for a total purchase price of
$676,455. The investor tendered the Note to the Company for cancellation and agreed to forego all future accrued interest under the Note,
as the total purchase price for the shares.
On June 19, 2023, the Company entered
into a securities purchase agreement with an accredited investor for an exchange of convertible debt to equity. Under the purchase agreement,
the Company and investor acknowledged there was an aggregate of $100,000 of principal outstanding under the Note issued to the investor
by the Company on August 10, 2018, plus $48,603 of accrued interest, representing a total aggregate note balance of $148,603. Pursuant
to the Purchase Agreement, the Company issued and sold to the investor 1,486 shares of the Company’s Series C Preferred
Stock for a total purchase price of $148,603, and a gain on settlement of debt of $3. The investor tendered the Note to the Company for
cancellation and agreed to forego all future accrued interest under the Note, as the total purchase price for the shares.
During the three months ended September
30, 2023, an investor converted 2,100 preferred shares with a stated value of $210,000, at a conversion price of $0.00095. The preferred
shares were converted into 221,052,632, no gain or loss was recognized in the financial statements.
The extinguishment of the convertible
debt and derivatives were recognized in the Company’s financial statement as a loss on settlement of convertible notes and derivative
liability in the amount of $664,627 as of June 30, 2023.
The Company had no derivative liabilities
outstanding at the years ended June 30, 2024 and 2023,
Exchange of convertible notes to Series C Preferred Shares | |
| |
Preferred shares issued | |
| 10,951 | |
Stated value of debt and interest | |
$ | 1,095,100 | |
Calculated fair value of preferred shares | |
$ | 17,475,309 | |
Fair value of derivative liability removed | |
$ | (16,810,682 | ) |
Loss on settlement of debt and derivatives | |
$ | (664,627 | ) |
The Series C Preferred Stock was presented
as mezzanine equity because it is redeemable at a fixed or determinable amount upon an event that is outside of the issuer’s control.
Upon liquidation, dissolution and winding up of the Company, the holder of each outstanding share of Series C Preferred Stock shall be
entitled to receive, out of the assets of the Company available for distribution to its shareholders upon such liquidation, before any
payments shall be made or any assets distributed to the holders of the common stock, the stated value of the Series C Preferred Shares
plus any declared but unpaid dividends. No other current or future equity holders of the Company shall have higher priority of liquidation
preference than holders of Series C Preferred Stock. The holder has the right, at any time, at its election, to convert shares of Series
C Preferred Stock into common stock at a conversion price of $0.00095 per share.
As of June 30, 2024 and 2023, the Company
had 8,851 and 10,951shares of Series C Preferred Stock outstanding, respectively. The fair value of the outstanding shares was $885,100
and1,095,100, respectively.
Year ended June 30, 2024
On November 11, 2022, the Company entered
into a Purchase Agreement with an investor for the sale of up to $45,000,000 of shares of common stock. For the year ended June 30,
2024, the Company issued 86,395,059 shares of common stock for $900,000 under the purchase agreement at prices of $0.00944 -
$0.0132, pursuant to purchase notices received from the investor. The finance cost of $21,075 was deducted from the gross proceeds
converted, leaving net proceeds of $878,925.
Year ended June 30, 2023
During the year ended June 30, 2023,
the Company issued 274,198,530 shares of common stock upon conversion of convertible notes in the amount of $177,500 of
principal, plus accrued interest of $82,989 based upon a conversion price of $0.00095 per share. The notes were converted per
the terms of their respective agreements and therefore no gain or loss on the conversion was recorded.
On November 11, 2022, the Company entered
into a Purchase Agreement with an investor for the sale of up to $45,000,000 of common stock. During the year ended June 30, 2023, the
Company issued 141,316,753 shares of common stock for $2,786,464 under the purchase agreement at prices of $0.01264 - $0.02608, pursuant
to purchase notices received from the investor. The finance cost of $52,970 was deducted from the gross proceeds converted, leaving net
proceeds of $2,733,494.
During the year ended June 30, 2023,
a consultant exercised 3,071,412 nonqualified stock options with an exercise price of $0.01 and a market price of $0.027 per
share. Upon exercise of the stock options, the Company issued 1,933,852 shares of common stock at the price of $0.017 per
share for compensation expense of $32,875.
During the year ended June 30, 2023,
two employees were granted 150,000,000 restricted stock awards for services, which vested immediately. The Company withheld 62,400,000 shares
at a price of $0.027 to pay for the taxes owed by the employees in the amount of $1,684,800, and the remaining 87,600,000 shares
priced at $0.027 per share in the amount of $2,365,200 in stock compensation was reported in the financial statements.
|
5. |
RESTRICTED STOCK UNITS |
On March 30, 2023, the Board of Directors
determined that in the best interest of the Company and the Shareholders to grant an employee a restricted stock units in consideration
of services to be rendered to the Company. The Board granted 21,500,000 of restricted stock units, which vested on March 30, 2023. Under
the 2019 Equity Incentive Plan, an employee was granted 21,500,000 restricted stock units at a price of $0.025 per share for
services, which vested on March 30, 2023. On January 30, 2024, the stock units of 21,500,000 were cancelled at a unit price of $0.012
in the amount of $258,000, which was netted against the stock compensation expense during the year
On December 20, 2022 and January 1,
2023, the Board of Directors determined that in the best interest of the Company and the Shareholders, to grant certain employees, a director,
and a consultant restricted stock units in consideration of services to be rendered to the Company. The Board granted 33,000,000 restricted
stock units under the 2022 Equity Incentive Plan, whereby, 23,000,000 shares vested on January 1, 2023 and 10,000,000 shares, which were
to vest on January 1, 2024, but were not granted. During the year ended June 30, 2024, the Company cancelled 20,000,000 of the stock units
at a price of $0.012 in the amount of $240,000, which was netted against the stock compensation expense during the period. The remaining
10,000,000 units were to vest on January 1, 2024 were not granted. As of June 30, 2024, there remained a balance of 3,000,000 stock units,
with an exercise price of $0.025.
The total stock units cancelled consisted
of 21,500,000 units for the 2019 Equity Incentive Plan and 20,000,000 units for the 2022 Equity Incentive Plan for an aggregate total
of 41,500,000. As of June 30, 2024, the Company recorded stock compensation expense of $689,984.
The fair value of the units was $618,000
for the 51,500,000 stock units.
| |
6/30/2024 | | |
6/30/2023 | |
| |
| | |
Weighted | | |
| | |
Weighted | |
| |
Number | | |
average | | |
Number | | |
average | |
| |
Of | | |
exercise | | |
Of | | |
exercise | |
| |
Units | | |
price | | |
Units | | |
price | |
Outstanding, beginning of period | |
| 54,500,000 | | |
$ | 0.025 | | |
| - | | |
$ | - | |
Granted | |
| - | | |
| - | | |
| 54,500,000 | | |
$ | 0.025 | |
Stock units not granted | |
| (10,000,000 | ) | |
| - | | |
| - | | |
| - | |
Cancellation of units | |
| (41,500,000 | ) | |
$ | 0.025 | | |
| - | | |
| - | |
Outstanding, end of period | |
| 3,000,000 | | |
$ | 0.025 | | |
| 54,500,000 | | |
$ | 0.025 | |
Exercisable at the end of period | |
| 3,000,000 | | |
$ | 0.025 | | |
| 54,500,000 | | |
$ | 0.025 | |
6. |
STOCK OPTIONS AND WARRANTS |
2019 Equity Stock Incentive Plan
On December 17, 2018, the Board of
Directors approved and adopted the 2019 Equity Incentive Plan (“the 2019 Plan”), with 300,000,000 shares reserved for issuance.
The purpose of the 2019 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means
through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The awards are performance-based
compensation that are granted under the 2019 Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise
price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option.
The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services
and for financing cost.
2022 Equity Stock Incentive Plan
On January 27, 2022, the Company adopted
the 2022 Equity Incentive Plan, to enable the Company to attract and retain the types of employees, consultants, and directors who will
contribute to the Company’s long-range success. The maximum number of shares of common stock that may be issued under the 2022 Plan
is initially 400,000,000. The number of shares will automatically be increased on the first day of the Company’s fiscal year
beginning in 2023 so that the total number of shares issuable will at all times equal fifteen percent (15%) of the Company’s fully
diluted capitalization on the first day of the Company’s fiscal year, unless the Board adopts a resolution providing that the
number of shares issuable under the 2022 Plan shall not be so increased.
As of July 1, 2023, the maximum number
of shares issuable under the 2022 Equity Incentive Plan increased by 15% to 723,194,742 shares, based on the Company’s fully diluted
capitalization on leaving a reserve of 660,194,742 shares remaining available as of June 30, 2024.
During the period ended June 30, 2024,
the Company granted 103,000,000 stock options at an exercise price of $0.012 per share, which vested immediately on January 30, 2024.
As of June 30, 2024, 266,894,499 stock options were outstanding, and the Company recognized stock compensation expense of $1,307,984.
A summary of the Company’s stock
option activity and related information follows:
| |
6/30/2024 | | |
6/30/2023 | |
| |
| | |
Weighted | | |
| | |
Weighted | |
| |
Number | | |
average | | |
Number | | |
average | |
| |
Of | | |
exercise | | |
Of | | |
exercise | |
| |
Options | | |
price | | |
Options | | |
price | |
Outstanding, beginning of period | |
| 163,894,499 | | |
$ | 0.0980 | | |
| 157,965,711 | | |
$ | 0.0089 | |
Granted | |
| 103,000,000 | | |
$ | 0.0120 | | |
| 9,000,000 | | |
$ | 0.0160 | |
Exercised | |
| - | | |
| | | |
| - | | |
| - | |
Redemption of options | |
| - | | |
| | | |
| (3,071,212 | ) | |
$ | (0.0100 | ) |
Outstanding, end of period | |
| 266,894,499 | | |
$ | 0.0107 | | |
| 163,894,499 | | |
$ | 0.0980 | |
Exercisable at the end of period | |
| 264,144,499 | | |
$ | 0.0105 | | |
| 157,894,499 | | |
$ | 0.0940 | |
The weighted average remaining contractual life of
options outstanding as of June 30, 2024 and 2023 was as follows:
6/30/2024 | | | 6/30/2023 | |
Exercise Price | | | Stock Options Outstanding | | | Stock Options Exercisable | | | Weighted Average Remaining Contractual Life (years) | | | Exercise Price | | | Stock Options Outstanding | | | Stock Options Exercisable | | | Weighted Average Remaining Contractual Life (years) | |
$ | 0.016 | | | | 9,000,000 | | | | 6,250,000 | | | | 1.92 | | | $ | 0.016 | | | | 9,000,000 | | | | 3,000,000 | | | | 2.92 | |
$ | 0.012 | | | | 103,000,000 | | | | 103,000,000 | | | | 5.59 | | | $ | - | | | | - | | | | - | | | | - | |
$ | 0.0097 | | | | 6,000,000 | | | | 6,000,000 | | | | 1.59 | | | $ | 0.0097 | | | | 6,000,000 | | | | 6,000,000 | | | | 2.59 | |
$ | 0.0099 | | | | 138,894,499 | | | | 138,894,499 | | | | 1.57 | | | $ | 0.0099 | | | | 138,894,499 | | | | 138,894,499 | | | | 2.57 | |
$ | 0.0060 | | | | 10,000,000 | | | | 10,000,000 | | | | 2.06 | | | $ | 0.0060 | | | | 10,000,000 | | | | 10,000,000 | | | | 3.06 | |
| | | | | 266,894,499 | | | | 264,144,499 | | | | | | | | | | | | 163,894,499 | | | | 157,894,499 | | | | | |
WARRANTS
During the year ended June 30, 2024,
8,400,000 common stock purchase warrants expired leaving an aggregate of 78,095,239 common stock purchase warrants outstanding, with an
exercise price of $0.121 per share. The warrants were estimated at fair value on the date of issuance as calculated using the Black-Scholes
valuation model. The derivative liability calculated on all warrants outstanding as of the Year ended June 30, 2024, was removed with
the exchange of the convertible notes and accrued interest for preferred shares. The warrants can be exercised over a period of three
(3) years.
A summary of the Company’s warrant
activity and related information follows for the Year ended June 30, 2024
| |
6/30/2024 | |
| |
| | |
Weighted | |
| |
| | |
average | |
| |
Number of | | |
exercise | |
| |
Warrants | | |
price | |
Outstanding, beginning of period | |
| 86,495,239 | | |
$ | 0.121 | |
Granted | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | |
Forfeited/Expired | |
| (8,400,000 | ) | |
$ | (0.094 | ) |
Outstanding, end of period | |
| 78,095,239 | | |
$ | 0.121 | |
Exercisable at the end of period | |
| 78,095,239 | | |
$ | 0.121 | |
The weighted average remaining contractual life of warrants
outstanding as of June 30, 2024 was as follows:
6/30/2024 | | | Weighted Average | |
Exercise Price | | | Warrants Outstanding | | | Warrants Exercisable | | | Remaining Contractual Life (years) | |
$ | 0.13125 | | | | 6,666,667 | | | | 6,666,667 | | | | 1.65 | |
$ | 0.12 | | | | 71,428,572 | | | | 71,428,572 | | | | 1.67 | |
| | | | | 78,095,239 | | | | 78,095,239 | | | | | |
At June 30, 2024, the aggregate intrinsic
value of the warrants outstanding was $0.
As of June 30, 2023, the Company invested
in corporate bonds, which were recognized in the financial statements at cost, mature from July 15, 2023 through August 16, 2023, and
were held to maturity.
The Company considers corporate bonds
(“bonds”) as investments due to their ratings. The bonds are rated based on their default probability, health of the corporation’s
debt structure, as well as the overall health of the economy. The bonds fall into the category as investments if they have a rating between
AA and BBB.
During the year ended June 30, 2024,
the corporate securities in the amount of $3,188,040 matured, and were redeemed on various dates for gross proceeds of $3,000,000. During
the years ended June 30, 2024 and 2023, the Company recorded interest income of $54,375 and $137,994, respectively. During the year ended
June 30, 2024, the Company recognized a loss of $188,040.
The following table summarizes the
amortized cost of the held-to-maturity securities as of June 30, 2023, aggregated by credit quality indicator.
| |
June 30,
2023 | |
AA/A | |
| | |
Corporate Securities | |
$ | 1,856,405 | |
BBB | |
| | |
Corporate Securities | |
| 1,331,635 | |
Total | |
$ | 3,188,040 | |
| 8. | EQUITY SECURITIES, RELATED PARTY AND CONVERTIBLE NOTES RECEIVABLE,
RELATED PARTY |
On November 11, 2022, the Company entered
into a subscription agreement with TECO 2030 ASA (“TECO”). TECO is a Norwegian based clean tech company developing zero-emission
technology for the maritime and heavy industry. They are developing PEM hydrogen fuel cell stacks and PEM hydrogen fuel cell modules,
that enable ships and other heavy-duty applications to become emissions-free. The company is listed on Euronext Growth on Oslo Stock Exchange
under the ticker TECO. Pursuant to the subscription agreement, the Company purchased 13,443,875 shares of TECO stock for an aggregate
consideration of $7 million in USD, at an exchange rate of NOK 10.4094. The stocks purchased are adjusted to fair value based on unrealized
gain or loss at the end of each period. At the time of this transaction, the Company and TECO became related parties due to the Company
owning an 8.3% interest in TECO. Subsequent to the equity purchase, Timothy Young, CEO of the Company, was elected to the board of TECO
in January of 2023.
Also, on November 11, 2022 the Company
purchased a bond receivable of TECO for a subscription amount of $3 million. The issuance of the bond receivable is through a Tap Issue
Addendum to TECO’s secured convertible notes agreement dated June 1, 2022, pursuant to which Nordic Trustee AS is acting as the
security agent on behalf of the note holders. The bond receivable would have matured on June 1, 2025, and would have been converted into
shares at a rate of NOK 5.0868 per share. The note bore interest at the rate of 8% per annum, which was paid quarterly in arrears. For
the year ended June 30, 2024 and 2023, the Company recognized interest income of $226,094 and $113,913, respectively.
In April of 2024, all investors of
TECO bonds received an option to convert their bonds to receive one share for every two NOK. On May 24, 2024 the Company agreed to the
terms and conversion, and agreed to receive 15,884,744 shares of TECO stock in exchange for the convertible bond receivable of $3,000,000
and unpaid interest. The bond receivable had a principal amount of NOK 31,228,200, and accrued and unpaid interest up to May 24, 2024
of NOK 541,289, for a total of NOK 31,769,489. The value of the shares converted on May 24, 2024 was $3,139,302 with contributed capital
gain on conversion of convertible bond of $85,815 and interest received of $53,487 as reflected in the statement of operations.
On September 10, 2024, after a delay
to allow time for legal review and clarification of the investment statements, the bond was returned. Upon receipt of the 15,884,744 shares,
the Company owns a total of 29,328,619 shares, which as of September 23, 2024 represents 13.29% of the outstanding shares of TECO.
The CEO of the Company elected to not
seek reelection to the board of directors at the annual general meeting in June and is no longer a director of TECO after June 19, 2024.
The CEO of the Company never received compensation of any kind for his role as director from January of 2023 through June 19, 2024.
The following table summarizes our
equity investments in TECO:
Date of Investment | |
Number of
Shares | | |
Cost Basis | | |
Fair
Value as of
June 30,
2022 | | |
Unrealized
Gain | | |
Fair
Value as of
June 30,
2023 | | |
Unrealized
Loss | | |
Fair
Value as of
June 30,
2024 | |
November 24, 2022 | |
| 13,443,875 | | |
$ | 7,000,000 | | |
$ | - | | |
$ | 655,601 | | |
$ | 7,655,601 | | |
$ | (5,775,569 | ) | |
$ | 1,880,032 | |
May 24, 2024 | |
| 15,884,744 | | |
| 3,139,302 | | |
| - | | |
| - | | |
| - | | |
| (917,932 | ) | |
| 2,221,370 | |
Total | |
| 29,328,619 | | |
$ | 10,139,302 | | |
$ | - | | |
$ | 655,601 | | |
$ | 7,655,601 | | |
$ | (6,693,501 | ) | |
$ | 4,101,402 | |
The following table summarizes our
investment income.
| |
June 30,
2024 | | |
June 30,
2023 | |
Interest earned on cash (NOTE 2) | |
$ | 455,772 | | |
$ | 257,661 | |
Interest earned on Treasury Bills (NOTE 2) | |
| 1,136,520 | | |
| 559,340 | |
Interest earned on Certificates of Deposit (NOTE 10) | |
| 123,881 | | |
| - | |
Interest earned on Corporate Bonds (NOTE 7) | |
| 54,375 | | |
| 137,994 | |
Interest earned on TECO bond (NOTE 8) | |
| 226,094 | | |
| 113,913 | |
Dividends and other | |
| 17,332 | | |
| 80,951 | |
Total investment income | |
$ | 2,013,974 | | |
$ | 1,149,859 | |
10. |
SHORT TERM INVESTMENTS |
On September 12, 2023, the Company
invested in a $5,000,000 certificate of deposit (CD), which matured on March 12, 2024. CDs should be reported as part of cash
and cash equivalents at cost plus accrued interest if less than 90 days from the purchase date, and on its own line in the financial statements
if the purchase is greater than 90 days. The CD has been classified as a short-term investment due to the length of time to maturity at
acquisition and was measured using Level 2. The certificate of the deposit matured, and was reinvested. The Company recognized interest
income of $123,881 in the financial statements as of June 30, 2024.
11. |
COMMITMENTS AND CONTINGENCIES |
Effective October 1, 2023, the Company
extended its research agreement with the University of Iowa through September 30, 2024. As consideration under the research agreement,
the University of Iowa will receive a maximum of $365,493 from the Company in four equal installments of $91,373. The agreement can
be terminated by either party upon sixty (60) days prior written notice to the other. As of June 30, 2024, there is a balance due of $274,121
per the agreement.
Effective October 1, 2023, the Company
extended its research agreement with the University of Michigan through September 30, 2024. As consideration under the research agreement,
the University of Michigan received payments of $223,645 on the $298,194 research agreement. The research agreement was amended for an
additional $85,000, which will be paid in four installments. . In the event of early termination by the Sponsor, the Sponsor will pay
all costs accrued by the University as of the date of termination, including non-cancellable obligations. As of June 30, 2024, there is
a balance due of $120,274 per the agreement.
The Company began renting lab space
in February 2022. The lab rental is on a month-to-month basis and is cancellable with a thirty (30) day notice. On April 1, 2024, the
Company renewed the space needed for its lab work at a monthly rent of $6,400 per month. Due to the rental being month-to-month, ASC 842
lease accounting is not applicable.
In the normal course of business, the Company
may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on the Company’s financial position or
results of operation.
The
Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no
longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2021.
Deferred
income taxes have been provided by temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for tax purposes. To the extent allowed by GAAP, we provide valuation allowances against the deferred tax
assets for amount when the realization is uncertain. Included in the balance at June 30, 2024 and 2023, are no tax positions for which
the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductibility. Because
of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would
not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period.
The
Company’s policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating
expenses. During the year ended June 30, 2024 and 2023, the Company did not recognize interest or penalties.
At
June 30, 2023, the Company had net operating loss carry-forward of approximately $25,304,800, which expires in future years. No tax benefit
has been reported in the June 30, 2024 and 2023 financial statements, since the potential tax benefit is offset by a valuation allowance
of the same amount.
The
income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from
continuing operations for the years ended June 30, 2024 and 2023 due to the following:
| |
6/30/2024 | | |
6/30/2023 | |
Book income (loss) | |
$ | (2,075,055 | ) | |
$ | 204,745 | |
Non-deductible expenses | |
| 1,535,200 | | |
| 1,975,885 | |
Depreciation and amortization | |
| 3,455 | | |
| (860 | ) |
Valuation Allowance | |
| 536,400 | | |
| (2,179,770 | ) |
| |
| | | |
| | |
Income tax expense | |
$ | - | | |
$ | - | |
Deferred taxes are provided on a liability
method, whereby deferred tax assets are recognized for deductible differences and operating loss and tax credit carry-forward and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the difference between the reported amounts
of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management,
it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities
are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets
will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of
enactment.
Net deferred tax liabilities consist
of the following components as of June 30, 2024 and 2023:
| |
6/30/2024 | | |
6/30/2023 | |
Deferred tax assets: | |
| | |
| |
NOL carryover | |
$ | (5,314,015 | ) | |
$ | (5,163,215 | ) |
Research and development | |
| 1,009,530 | | |
| 736,330 | |
Related party accrual | |
| 9,625 | | |
| 30,125 | |
Deferred tax liabilities: | |
| | | |
| | |
Depreciation and amortization | |
| (3,095 | ) | |
| (4,485 | ) |
| |
| | | |
| | |
Less Valuation Allowance | |
$ | 4,297,955 | | |
$ | 4,401,245 | |
| |
| | | |
| | |
Income tax expense | |
$ | - | | |
$ | - | |
Due to the change in ownership provisions
of the Tax Reform Act of 1986, net operating loss carry-forward for Federal income tax reporting purposes are subject to annual limitations.
Should a change in ownership occur, net operating loss carry-forward may be limited as to use in future years.
The Company’s tax returns for
the previous three years remain open for audit by the respective tax jurisdictions.
Shareholders Loan
As of June 30, 2024, the Company reported
an accrual associated with the CEO’s prior years’ salary in the amount of $211,750 for the current year, which is recorded
in related party accrued expenses. The Company began accruing the salary in 2011 and used the funds for operating expenses. During the
period ended December 31, 2022, the accrued salary was reclassified as a loan from the CEO, with an interest rate of five percent (5%).
The loan will be repaid with monthly payments of $9,290, including interest and principal over a two-year period. As of June 30, 2024,
the principal balance remaining on the loan was $45,829, and interest paid during the year ended June 30, 2024 was $4,558.
Other Related Party Activity
See Note 8 for related party transactions
with respect to TECO 2030 A.S.A.. for 2023 and 2024 periods.
14. |
CONVERTIBLE PROMISSORY NOTES |
As of June 30, 2024 and 2023, there
were no outstanding convertible promissory notes. All convertible notes were exchanged for Series C Preferred Shares.
The Company issued a 10% convertible
promissory note on November 9, 2017 (the “Nov 2017 Note”) in the aggregate principal amount of up to $500,000. The Company
received tranches for an aggregate principal total of $500,000. The Nov 2017 Note had a maturity date of November 9, 2018, with an automatic
extension of sixty (60) months from the effective date of the note. The Nov 2017 Note is convertible into shares of common stock of the
Company at a price equal to a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading
price since the original effective date of the note or the lowest effective price per share granted to any person or entity after the
effective date to acquire common stock. If the Company fails to deliver shares in accordance with the timeframe of three (3) business
days of the receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion,
in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned
to the principal sum with the rescinded conversion shares returned to the Company. In no event shall the lender be entitled to convert
any portion of the Nov 2017 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of
more than 4.99% of the outstanding shares of common stock of the Company. In addition, for each conversion in the event that shares
are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed
for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. During the year ended
June 30, 2023, the Company issued 274,198,530 shares of common stock upon the conversion of principal in the amount of $177,500,
plus accrued interest of $82,989. As of June 30, 2023, the balance remaining was $0.
The Company issued a 10% convertible
promissory note on June 27, 2018 (the “Jun 2018 Note”) in the aggregate principal amount of up to $500,000. The Company received
tranches for an aggregate principal total of $500,000. The Jun 2018 Note matured on June 27, 2019, which was automatically extended for
sixty (60) months from the effective date of the note. The Jun 2018 Note is convertible into shares of common stock of the Company at
a price equal to a variable conversion price of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price
since the original effective date of the note or the lowest effective price per share granted to any person or entity after the effective
date to acquire common stock. If the Company fails to deliver shares in accordance with the timeframe of three (3) business days of the
receipt of a notice of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion, in whole or
in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal
sum with the rescinded conversion shares returned to the Company. In no event shall the lender be entitled to convert any portion of the
Jun 2018 Note to the extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99%
of the outstanding shares of common stock of the Company. In addition, for each conversion, in the event, that shares are not delivered
by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after
the third business day (inclusive of the day of the conversion) until the shares are delivered. The balance of the Jun 2018 Note of $500,000,
plus interest was exchanged for Series C Preferred Shares, leaving a remaining balance at June 30, 2023 of $0.
The Company issued a 10% convertible
promissory note on August 10, 2018 (the “Aug 2018 Note”) in the aggregate principal amount of up to $100,000. The Aug
2018 Note had a maturity date of August 10, 2019, with an extension of sixty (60) months from the date of the note. The Aug 2018 Note
matures on August 10, 2023. The Aug 2018 Note may be converted into shares of the Company’s common stock at a conversion price
of the lesser of a) $0.005 per share or b) sixty-one (61%) percent of the lowest trading price per common stock recorded on any trade
day after the effective date. The conversion feature of the Aug 2018 Note was considered a derivative in accordance with current accounting
guidelines because of the reset conversion features of the Note. The balance of the Aug 2018 Note of $100,000, plus interest was exchanged
for Series C Preferred Shares, leaving a remaining balance at June 30, 2023 of $0.
On April 15, 2020, the Company issued
a convertible promissory note (the “Apr 2020 Note”) to an investor in the aggregate principal amount of $50,000. The Company
received tranches for an aggregate principal total of $50,000. The Apr 2020 Note matures twelve (12) months from the effective dates of
each respective tranche, such that the Apr 2020 Note matures on April 15, 2021, with an automatic extension of sixty (60) months from
the effective date of each tranche. The Apr Note is convertible into shares of common stock of the Company at a variable conversion price
of the lesser of $0.01 per share or fifty percent (50%) of the lowest trading price of the common stock recorded on any trade day
after the effective date, or (c) the lowest effective price per share granted to any person or entity after the effective date to acquire
common stock. If the Company fails to deliver shares in accordance with the timeframe of four (4) business days of the receipt of a notice
of conversion, the lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular
conversion attributable to the unsold shares and have the rescinded conversion amount returned to the principal sum with the rescinded
conversion shares returned to the Company. In no event shall the lender be entitled to convert any portion of the Apr 2020 Note to the
extent such conversion would result in beneficial ownership by the lender and its affiliates of more than 4.99% of the outstanding
shares of common stock of the Company. In addition, for each conversion, in the event that shares are not delivered by the fourth business
day (inclusive of the day of conversion), a penalty of $2,000 per day shall be assessed for each day after the fourth business day
(inclusive of the day of the conversion) until the shares are delivered. The conversion feature of the April 2020 Note was considered
a derivative in accordance with current accounting guidelines because of the reset conversion features of the Apr 2020 Note. The balance
of the Apr 2020 Note of $50,000, plus interest was exchanged for Series C Preferred Shares, leaving a remaining balance as of June 30,
2023 of $0.
15. | DERIVATIVE
LIABILITIES |
ASC Topic 815 provides guidance applicable
to convertible debt issued by the Company in instances where the number into which the debt can be converted is not fixed. For example,
when a convertible debt converts at a discount to market based on the stock price on the date of conversion, ASC Topic 815 requires that
the embedded conversion option of the convertible debt be bifurcated from the host contract and recorded at their fair value. In accounting
for derivatives under accounting standards, the Company recorded a liability representing the estimated present value of the conversion
feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated
with the embedded derivative. The discount is amortized over the life of the convertible debt, and the derivative liability is adjusted
periodically according to stock price fluctuations.
In
accordance with ASC No. 820, “Fair Value Measurements and Disclosures”, the Company measures its liability related to convertible
notes and warrants at fair value using Black Scholes. They are valued using alternative pricing sources and models utilizing market observable
inputs. The liability related to the convertible notes and warrants is classified within Level 3 value hierarchy because the liability
is based on present value calculations and external valuation models whose inputs include market interest rates, estimated operational
capitalization rates, volatilities and illiquidity. Unobservable inputs used in these models are significant.
During the year ended June 30, 2023,
the Company recorded a net gain change in derivative of $9,204,387 in the statement of operations, due to the removal of the derivatives
for the warrants and the convertible notes, for the exchange of the convertible notes and accrued interest for Series C Preferred Shares.
Management evaluated subsequent events
as of the date of the financial statements pursuant to ASC TOPIC 855 and had the following subsequent events to report.
On September 6, 2024, the
Company issued 32,051,283 shares of common stock at a price of $0.0156 per share in the amount of $500,000, pursuant to a purchase notice
under the purchase agreement.
On September 13, 2024, the
Company issued 37,055,336 shares of common stock at a price of $0.02024 per share in the amount of $750,000, pursuant to a purchase notice
under the purchase agreement.
On September 16, 2024, Mark Richardson
resigned as a director of SunHydrogen, Inc. Mr. Richardson’s resignation will be effective September 30, 2024. Mr. Richardson’s
resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies
or practices.
On September 30, 2024, the Company
issued 49,407,115 shares of common stock at a price of $0.02024 per share in the amount of $1,000,000, pursuant to a purchase notice under
the purchase agreement.
NONE
1095100
10951
false
FY
0001481028
0001481028
2023-07-01
2024-06-30
0001481028
2023-12-31
0001481028
2024-09-30
0001481028
2024-06-30
0001481028
2023-06-30
0001481028
us-gaap:RelatedPartyMember
2024-06-30
0001481028
us-gaap:RelatedPartyMember
2023-06-30
0001481028
us-gaap:OtherIntangibleAssetsMember
2024-06-30
0001481028
us-gaap:OtherIntangibleAssetsMember
2023-06-30
0001481028
us-gaap:TrademarksMember
2024-06-30
0001481028
us-gaap:TrademarksMember
2023-06-30
0001481028
us-gaap:TradeSecretsMember
2024-06-30
0001481028
us-gaap:TradeSecretsMember
2023-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2024-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2023-06-30
0001481028
2022-07-01
2023-06-30
0001481028
us-gaap:PreferredStockMember
2023-06-30
0001481028
hysr:MezzanineMember
2023-06-30
0001481028
us-gaap:CommonStockMember
2023-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001481028
us-gaap:RetainedEarningsMember
2023-06-30
0001481028
us-gaap:PreferredStockMember
2023-07-01
2024-06-30
0001481028
hysr:MezzanineMember
2023-07-01
2024-06-30
0001481028
us-gaap:CommonStockMember
2023-07-01
2024-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2024-06-30
0001481028
us-gaap:RetainedEarningsMember
2023-07-01
2024-06-30
0001481028
us-gaap:PreferredStockMember
2024-06-30
0001481028
hysr:MezzanineMember
2024-06-30
0001481028
us-gaap:CommonStockMember
2024-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001481028
us-gaap:RetainedEarningsMember
2024-06-30
0001481028
us-gaap:PreferredStockMember
2022-06-30
0001481028
hysr:MezzanineMember
2022-06-30
0001481028
us-gaap:CommonStockMember
2022-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001481028
us-gaap:RetainedEarningsMember
2022-06-30
0001481028
2022-06-30
0001481028
us-gaap:PreferredStockMember
2022-07-01
2023-06-30
0001481028
hysr:MezzanineMember
2022-07-01
2023-06-30
0001481028
us-gaap:CommonStockMember
2022-07-01
2023-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2023-06-30
0001481028
us-gaap:RetainedEarningsMember
2022-07-01
2023-06-30
0001481028
2024-04-01
2024-06-30
0001481028
hysr:DilutiveImpactsMember
2023-07-01
2024-06-30
0001481028
hysr:DilutiveImpactsMember
2024-06-30
0001481028
hysr:DilutiveImpactsMember
us-gaap:SeriesCPreferredStockMember
2024-06-30
0001481028
hysr:DilutiveImpactsMember
2022-07-01
2023-06-30
0001481028
hysr:DilutiveImpactsMember
2023-06-30
0001481028
hysr:DilutiveImpactsMember
us-gaap:SeriesCPreferredStockMember
2022-07-01
2023-06-30
0001481028
hysr:DilutiveImpactsMember
us-gaap:SeriesCPreferredStockMember
2023-06-30
0001481028
hysr:TwoThousandTwentyTwoEquityIncentivePlansMember
2022-01-27
2022-01-27
0001481028
hysr:TwoThousandTwentyTwoEquityIncentivePlansMember
2023-07-01
2024-06-30
0001481028
hysr:TwoThousandTwentyTwoEquityIncentivePlansMember
2024-06-30
0001481028
hysr:TwoThousandNineteenEquityIncentivePlanMember
2018-12-17
0001481028
hysr:TwoThousandNineteenEquityIncentivePlanMember
2018-12-17
2018-12-17
0001481028
hysr:TwoThousandNineteenEquityIncentivePlanMember
2023-07-01
2024-06-30
0001481028
hysr:TwoThousandNineteenEquityIncentivePlanMember
2024-06-30
0001481028
us-gaap:CashMember
2024-06-30
0001481028
us-gaap:CashMember
2023-06-30
0001481028
us-gaap:USTreasuryBillSecuritiesMember
2024-06-30
0001481028
us-gaap:USTreasuryBillSecuritiesMember
2023-06-30
0001481028
hysr:USTreasuryObligationsMember
2024-06-30
0001481028
hysr:USTreasuryObligationsMember
2023-06-30
0001481028
us-gaap:ComputerEquipmentMember
2024-06-30
0001481028
us-gaap:VehiclesMember
2024-06-30
0001481028
hysr:DomainMember
2024-06-30
0001481028
hysr:DomainMember
2023-06-30
0001481028
us-gaap:TrademarksMember
2024-06-30
0001481028
us-gaap:TrademarksMember
2023-06-30
0001481028
us-gaap:PatentsMember
2024-06-30
0001481028
us-gaap:PatentsMember
2023-06-30
0001481028
us-gaap:FairValueInputsLevel1Member
2024-06-30
0001481028
us-gaap:FairValueInputsLevel2Member
2024-06-30
0001481028
us-gaap:FairValueInputsLevel3Member
2024-06-30
0001481028
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001481028
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001481028
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001481028
us-gaap:FairValueInputsLevel3Member
2022-06-30
0001481028
us-gaap:FairValueInputsLevel3Member
2022-07-01
2023-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2021-12-15
0001481028
us-gaap:SeriesCPreferredStockMember
2021-12-15
2021-12-15
0001481028
hysr:InvestorsMember
us-gaap:SeriesCPreferredStockMember
2024-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2023-07-01
2024-06-30
0001481028
2023-04-15
0001481028
2023-06-19
0001481028
2023-04-15
2023-04-15
0001481028
2023-06-19
2023-06-19
0001481028
hysr:PurchaseAgreementMember
2021-12-15
0001481028
hysr:PurchaseAgreementMember
2017-02-03
2017-02-03
0001481028
hysr:PurchaseAgreementMember
2017-02-03
0001481028
2017-02-03
2017-02-03
0001481028
us-gaap:SeriesCPreferredStockMember
2017-02-03
0001481028
us-gaap:SeriesCPreferredStockMember
2023-04-15
0001481028
hysr:ConvertiblePromissoryNotesMember
2023-06-19
0001481028
us-gaap:SeriesCPreferredStockMember
2023-06-19
0001481028
us-gaap:SeriesCPreferredStockMember
2023-09-30
0001481028
2023-07-01
2023-09-30
0001481028
us-gaap:CommonStockMember
2023-09-30
0001481028
2023-09-30
0001481028
hysr:PurchaseAgreementMember
us-gaap:CommonStockMember
2022-11-11
2022-11-11
0001481028
us-gaap:CommonStockMember
2023-07-01
2024-06-30
0001481028
us-gaap:CommonStockMember
2022-07-01
2023-06-30
0001481028
us-gaap:CommonStockMember
2023-06-30
0001481028
us-gaap:CommonStockMember
2022-11-11
2022-11-11
0001481028
us-gaap:StockOptionMember
2023-06-30
0001481028
us-gaap:StockOptionMember
2022-07-01
2023-06-30
0001481028
hysr:EmployeesMember
us-gaap:CommonStockMember
2022-07-01
2023-06-30
0001481028
hysr:EmployeesMember
us-gaap:SeriesCPreferredStockMember
2023-06-30
0001481028
hysr:RestrictedStockAwardsMember
2023-03-30
2023-03-30
0001481028
hysr:StockOptionPlanMember
hysr:RestrictedStockAwardsMember
2023-03-30
2023-03-30
0001481028
hysr:StockOptionPlanMember
hysr:RestrictedStockAwardsMember
2023-03-30
0001481028
hysr:StockOptionPlanMember
hysr:RestrictedStockAwardsMember
2024-01-30
0001481028
hysr:StockOptionPlanMember
hysr:RestrictedStockAwardsMember
2024-01-30
2024-01-30
0001481028
hysr:RestrictedStockAwardsMember
2023-01-01
2023-01-01
0001481028
2023-01-01
2023-01-01
0001481028
hysr:ConsultantMember
hysr:RestrictedStockAwardsMember
2023-07-01
2024-06-30
0001481028
us-gaap:ServiceMember
hysr:StockOptionPlanMember
2024-06-30
0001481028
hysr:RestrictedStockAwardsMember
2023-07-01
2024-06-30
0001481028
us-gaap:RestrictedStockUnitsRSUMember
2024-01-01
2024-01-01
0001481028
hysr:StockOptionPlanMember
2024-06-30
0001481028
hysr:TwentyNineteenEquityIncentivePlanMember
2023-07-01
2024-06-30
0001481028
hysr:TwentyTwentyTwoEquityIncentivePlanMember
2023-07-01
2024-06-30
0001481028
us-gaap:RestrictedStockMember
2023-06-30
0001481028
us-gaap:RestrictedStockMember
2022-06-30
0001481028
us-gaap:RestrictedStockMember
2023-07-01
2024-06-30
0001481028
us-gaap:RestrictedStockMember
2022-07-01
2023-06-30
0001481028
us-gaap:RestrictedStockMember
2024-06-30
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
us-gaap:StockOptionMember
hysr:RestricedStockAwardsMember
2018-12-17
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2018-12-17
2018-12-17
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
hysr:EquityIncentiveMember
2022-01-27
2022-01-27
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2022-01-27
2022-01-27
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2023-07-01
2023-07-01
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2023-07-01
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2023-07-01
2024-06-30
0001481028
us-gaap:WarrantMember
2023-07-01
2024-06-30
0001481028
us-gaap:WarrantMember
2024-06-30
0001481028
hysr:ZeroPointZeroOneSixMember
2024-06-30
0001481028
hysr:ZeroPointZeroOneSixMember
2023-07-01
2024-06-30
0001481028
hysr:ZeroPointZeroOneSixMember
2023-06-30
0001481028
hysr:ZeroPointZeroOneSixMember
2022-07-01
2023-06-30
0001481028
hysr:ZeroPointZeroOneTwoMember
2024-06-30
0001481028
hysr:ZeroPointZeroOneTwoMember
2023-07-01
2024-06-30
0001481028
hysr:ZeroPointZeroOneTwoMember
2023-06-30
0001481028
hysr:ZeroPointZeroOneTwoMember
2022-07-01
2023-06-30
0001481028
hysr:ZeroPointZeroZeroNineSevenMember
2024-06-30
0001481028
hysr:ZeroPointZeroZeroNineSevenMember
2023-07-01
2024-06-30
0001481028
hysr:ZeroPointZeroZeroNineSevenMember
2023-06-30
0001481028
hysr:ZeroPointZeroZeroNineSevenMember
2022-07-01
2023-06-30
0001481028
hysr:ZeroPointZeroZeroNineNineMember
2024-06-30
0001481028
hysr:ZeroPointZeroZeroNineNineMember
2023-07-01
2024-06-30
0001481028
hysr:ZeroPointZeroZeroNineNineMember
2023-06-30
0001481028
hysr:ZeroPointZeroZeroNineNineMember
2022-07-01
2023-06-30
0001481028
hysr:ZeroPointZeroZeroSixZeroMember
2024-06-30
0001481028
hysr:ZeroPointZeroZeroSixZeroMember
2023-07-01
2024-06-30
0001481028
hysr:ZeroPointZeroZeroSixZeroMember
2023-06-30
0001481028
hysr:ZeroPointZeroZeroSixZeroMember
2022-07-01
2023-06-30
0001481028
us-gaap:WarrantMember
2023-06-30
0001481028
hysr:ExercisePriceOneMember
2024-06-30
0001481028
hysr:ExercisePriceOneMember
2023-07-01
2024-06-30
0001481028
hysr:ExercisePriceTwoMember
2024-06-30
0001481028
hysr:ExercisePriceTwoMember
2023-07-01
2024-06-30
0001481028
us-gaap:CorporateMember
2024-06-30
0001481028
us-gaap:CorporateMember
2023-07-01
2024-06-30
0001481028
hysr:AAACorporateSecuritiesMember
2023-06-30
0001481028
hysr:BBBCorporateSecuritiesMember
2023-06-30
0001481028
2022-11-01
2022-11-11
0001481028
2022-11-11
0001481028
hysr:InterestEarnedOnTECOBondMember
2023-07-01
2024-06-30
0001481028
hysr:InterestEarnedOnTECOBondMember
2022-07-01
2023-06-30
0001481028
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
us-gaap:InvestorMember
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
2024-09-10
0001481028
2024-09-10
0001481028
hysr:TECOMember
2024-09-10
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2021-07-01
2022-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2022-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2022-07-01
2023-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2023-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2023-07-01
2024-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyFourMember
2024-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2021-07-01
2022-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2022-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2022-07-01
2023-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2023-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2023-07-01
2024-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
2024-06-30
0001481028
2021-07-01
2022-06-30
0001481028
hysr:InterestEarnedOnCashMember
2023-07-01
2024-06-30
0001481028
hysr:InterestEarnedOnCashMember
2022-07-01
2023-06-30
0001481028
hysr:InterestEarnedOnTreasuryBillsMember
2023-07-01
2024-06-30
0001481028
hysr:InterestEarnedOnTreasuryBillsMember
2022-07-01
2023-06-30
0001481028
hysr:InterestEarnedOnCertificatesOfDepositMember
2023-07-01
2024-06-30
0001481028
hysr:InterestEarnedOnCertificatesOfDepositMember
2022-07-01
2023-06-30
0001481028
hysr:InterestEarnedOnCorporateBondsMember
2023-07-01
2024-06-30
0001481028
hysr:InterestEarnedOnCorporateBondsMember
2022-07-01
2023-06-30
0001481028
hysr:DividendsAndOtherMember
2023-07-01
2024-06-30
0001481028
hysr:DividendsAndOtherMember
2022-07-01
2023-06-30
0001481028
2023-09-12
0001481028
us-gaap:CertificatesOfDepositMember
2024-06-30
0001481028
us-gaap:CertificatesOfDepositMember
2023-07-01
2024-06-30
0001481028
hysr:UniversityOfIowaMember
2023-10-01
0001481028
hysr:UniversityOfIowaMember
2023-10-01
2023-10-01
0001481028
hysr:UniversityOfIowaMember
2023-07-01
2024-06-30
0001481028
hysr:UniversityOfMichiganMember
2023-10-01
0001481028
hysr:ResearchAgreementMember
2023-10-01
0001481028
hysr:UniversityOfMichiganMember
2023-10-01
2023-10-01
0001481028
2024-04-01
0001481028
srt:ChiefExecutiveOfficerMember
us-gaap:RelatedPartyMember
2024-06-30
0001481028
2022-07-01
2022-12-31
0001481028
hysr:LoanMember
2023-07-01
2024-06-30
0001481028
hysr:ConvertiblePromissoryNoteMember
2017-11-09
0001481028
hysr:NovemberTwoThousandSeventeenNoteMember
2024-06-30
0001481028
hysr:NovemberTwoThousandSeventeenNoteMember
2023-07-01
2024-06-30
0001481028
hysr:ConvertiblePromissoryNoteMember
2023-07-01
2024-06-30
0001481028
us-gaap:LineOfCreditMember
2022-07-01
2023-06-30
0001481028
us-gaap:LineOfCreditMember
2023-06-30
0001481028
hysr:ConvertiblePromissoryNoteMember
2018-06-27
0001481028
hysr:JuneTwentySevenTwoThousandAndEighteenNoteMember
2024-06-30
0001481028
hysr:JuneTwentySevenTwoThousandAndEighteenNoteMember
2023-07-01
2024-06-30
0001481028
us-gaap:LineOfCreditMember
us-gaap:SeriesCPreferredStockMember
2022-07-01
2023-06-30
0001481028
us-gaap:LineOfCreditMember
us-gaap:SeriesCPreferredStockMember
2023-06-30
0001481028
hysr:ConvertiblePromissoryNoteMember
2018-08-10
0001481028
hysr:AugustTenTwoThousandAndEighteenNoteMember
2024-06-30
0001481028
hysr:AugustTenTwoThousandAndEighteenNoteMember
us-gaap:CommonStockMember
2024-06-30
0001481028
us-gaap:LineOfCreditMember
2024-06-30
0001481028
hysr:ConvertiblePromissoryNoteMember
2024-06-30
0001481028
hysr:AprilTwoThousandAndTwentyNoteMember
2024-06-30
0001481028
hysr:AprilTwoThousandAndTwentyNoteMember
2020-04-15
0001481028
hysr:AprilTwoThousandAndTwentyNoteMember
2020-04-15
0001481028
hysr:AprilTwoThousandAndTwentyNoteMember
2020-04-15
2020-04-15
0001481028
us-gaap:SeriesCPreferredStockMember
2020-04-30
2020-04-30
0001481028
hysr:AprilTwoThousandAndTwentyNoteMember
2020-04-30
0001481028
us-gaap:SubsequentEventMember
2024-09-06
0001481028
us-gaap:SubsequentEventMember
2024-09-13
0001481028
srt:ScenarioForecastMember
2024-09-30
iso4217:USD
xbrli:shares
xbrli:pure
iso4217:USD
xbrli:shares
iso4217:NOK
xbrli:shares
iso4217:NOK
We consent to the incorporation by reference in
the Registration Statement on Form S-3 (File No. 333-276678) and Registration Statements on Form S-8 (File Nos. 333-228900 and 333-268887)
of our report, dated September 30, 2024, relating to the financial statements of SunHydrogen, Inc. for the years ended June 30, 2024 and
June 30, 2023, which appear in this Form 10-K.
In connection with the Annual
Report of SunHydrogen, Inc. (the “Company”) on Form 10-K for the fiscal year ended June 30, 2024, as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Timothy Young, Chief Executive Officer & Acting Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that: